<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Eszopiclone for insomnia - Rösner, S - 2018 | Cochrane Library</title> <meta content="Eszopiclone for insomnia - Rösner, S - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Eszopiclone for insomnia - Rösner, S - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010703.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Eszopiclone for insomnia" name="citation_title"/> <meta content="Susanne Rösner" name="citation_author"/> <meta content="Forel Klinik" name="citation_author_institution"/> <meta content="susanne.roesner@forel-klinik.ch" name="citation_author_email"/> <meta content="Christian Englbrecht" name="citation_author"/> <meta content="Forel Klinik" name="citation_author_institution"/> <meta content="Renate Wehrle" name="citation_author"/> <meta content="EasyCap" name="citation_author_institution"/> <meta content="Göran Hajak" name="citation_author"/> <meta content="Social Foundation Bamberg" name="citation_author_institution"/> <meta content="Michael Soyka" name="citation_author"/> <meta content="University of Munich" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010703.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Eszopiclone [*therapeutic use]; Hypnotics and Sedatives [*therapeutic use]; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders [*drug therapy]; Time Factors; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010703.pub2&amp;doi=10.1002/14651858.CD010703.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010703\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010703\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","th","ms","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010703.pub2",title:"Eszopiclone for insomnia",firstPublishedDate:"Oct 10, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010703.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010703.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010703.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010703.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010703.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010703.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010703.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010703.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010703.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010703.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11199 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010703.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0128"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-sec-0116"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/appendices#CD010703-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/table_n/CD010703StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/table_n/CD010703StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Eszopiclone for insomnia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#CD010703-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Susanne Rösner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#CD010703-cr-0003">Christian Englbrecht</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#CD010703-cr-0004">Renate Wehrle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#CD010703-cr-0005">Göran Hajak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information#CD010703-cr-0006">Michael Soyka</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information/en#CD010703-sec-0138">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010703.pub2">https://doi.org/10.1002/14651858.CD010703.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010703-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010703-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010703-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010703-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010703-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD010703-abs-0002">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010703-abs-0001" lang="en"> <section id="CD010703-sec-0001"> <h3 class="title" id="CD010703-sec-0001">Background</h3> <p>Insomnia is a major public health issue affecting between 6% to 10% of the adult population in Western countries. Eszopiclone is a hypnotic drug belonging to a newer group of hypnotic agents, known as new generation hypnotics, which was marketed as being just as effective as benzodiazepines for this condition, while being safer and having a lower risk for abuse and dependence. It is the aim of the review to integrate evidence from randomised controlled trials and to draw conclusions on eszopiclone's efficacy and safety profile, while taking methodological features and bias risks into consideration. </p> </section> <section id="CD010703-sec-0002"> <h3 class="title" id="CD010703-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of eszopiclone for the treatment of insomnia compared to placebo or active control. </p> </section> <section id="CD010703-sec-0003"> <h3 class="title" id="CD010703-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled trials (CENTRAL), MEDLINE, Embase, PsycINFO, PSYNDEX and registry databases (WHO trials portal, ClinicalTrials.gov) with results incorporated from searches to 10 February 2016. To identify trials not registered in electronic databases, we contacted key informants and searched reference lists of identified studies. We ran an update search (21 February 2018) and have placed studies of interest in awaiting classification/ongoing studies. These will be incorporated into the next version of the review, as appropriate. </p> </section> <section id="CD010703-sec-0004"> <h3 class="title" id="CD010703-sec-0004">Selection criteria</h3> <p>Parallel group randomised controlled trials (RCTs) comparing eszopiclone with either placebo or active control were included in the review. Participants were adults with insomnia, as diagnosed with a standardised diagnostic system, including primary insomnia and comorbid insomnia. </p> </section> <section id="CD010703-sec-0005"> <h3 class="title" id="CD010703-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted outcome data; one reviewer assessed trial quality and the second author cross‐checked it. </p> </section> <section id="CD010703-sec-0006"> <h3 class="title" id="CD010703-sec-0006">Main results</h3> <p>A total of 14 RCTs, with 4732 participants, were included in this review covering short‐term (≤ 4 weeks; 6 studies), medium‐term (&gt; 4 weeks ≤ 6 months; 6 studies) and long‐term treatment (&gt; 6 months; 2 studies) with eszopiclone. Most RCTs included in the review included participants aged between 18 and 64 years, three RCTs only included elderly participants (64 to 85 years) and one RCT included participants with a broader age range (35 to 85 years). Seven studies considered primary insomnia; the remaining studies considered secondary insomnia comorbid with depression (2), generalised anxiety (1), back pain (1), Parkinson's disease (1), rheumatoid arthritis (1) and menopausal transition (1). </p> <p>Meta‐analytic integrations of participant‐reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo: a 12‐minute decrease of sleep onset latency (mean difference (MD) ‐11.94 min, 95% confidence interval (CI) ‐16.03 to ‐7.86; 9 studies, 2890 participants, moderate quality evidence), a 17‐minute decrease of wake time after sleep onset (MD ‐17.02 min, 95% CI ‐24.89 to ‐9.15; 8 studies, 2295 participants, moderate quality evidence) and a 28‐minute increase of total sleep time (MD 27.70 min, 95% CI 20.30 to 35.09; 10 studies, 2965 participants, moderate quality evidence). There were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency (MD 17.00 min, 95% CI ‐4.29 to 38.29; 1 study, 291 participants, low quality evidence) and wake time after sleep onset (MD ‐6.71 min, 95% CI ‐21.25 to 7.83; 1 study, 291 participants, low quality evidence). Adverse events during treatment that were documented more frequently under eszopiclone compared to placebo included unpleasant taste (risk difference (RD) 0.18, 95% CI 0.14 to 0.21; 9 studies, 3787 participants), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; 6 studies, 2802 participants), somnolence (RD 0.04, 95% CI 0.02 to 0.06; 8 studies, 3532 participants) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; 7 studies, 2933 participants). According to the GRADE criteria, evidence was rated as being of moderate quality for sleep efficacy outcomes and adverse events and of low quality for rebound effects and next‐day functioning. </p> </section> <section id="CD010703-sec-0007"> <h3 class="title" id="CD010703-sec-0007">Authors' conclusions</h3> <p>Eszopiclone appears to be an efficient drug with moderate effects on sleep onset and maintenance. There was no or little evidence of harm if taken as recommended. However, as certain patient subgroups were underrepresented in RCTs included in the review, findings might not have displayed the entire spectrum of possible adverse events. Further, increased caution is required in elderly individuals with cognitive and motor impairments and individuals who are at increased risk of using eszopiclone in a non‐recommended way. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010703-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010703-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010703-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010703-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010703-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010703-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010703-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010703-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD010703-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010703-abs-0005" lang="en"> <h3>Eszopiclone (Lunesta) for sleep difficulty</h3> <p><b>Why is this review important?</b> </p> <p>Insomnia is the medical term for sleep difficulty covering trouble falling asleep, difficulties staying asleep, waking up too early or experiencing sleep as non‐restorative. Insomnia can be treated with different methods including behaviour modification, relaxation techniques, or sleeping medication. Eszopiclone (Lunesta) is a sleeping medication that belongs to a class of sleeping tablets known as non‐benzodiazepine hypnotics. </p> <p><b>Who will be interested in this review?</b> </p> <p>People who are affected by insomnia, general practitioners, professionals working in health services, and addiction treatment and health policy makers. </p> <p><b>What questions does this review aim to answer?</b> </p> <p>The review aimed to find out more about the wanted effects and unwanted effects of eszopiclone. Wanted effects included the immediate effects eszopiclone has on sleep; unwanted effects included side effects, effects on next‐day functioning, but also addictive properties of the drug. </p> <p><b>Which studies were included in the review?</b> </p> <p>The review summarised findings from 14 clinical studies with 4732 people, either receiving eszopiclone or an identically‐appearing, but inert substance (placebo). </p> <p><b>What does the evidence from the review tell us?</b> </p> <p>On average, people taking eszopiclone fell asleep 12 minutes faster than those taking placebo, were 17 minutes less awake during the night and had, in total, about half an hour more sleep than people in the placebo group. As side effects, eszopiclone can cause unpleasant taste, dizziness, dry mouth, and tiredness during the day. Clinical studies did not find evidence that eszopiclone was causing serious harm or withdrawal symptoms or whether it was addictive if it was stopped and not taken after several weeks or months of treatment. Nevertheless, as clinical studies included in the review did not cover certain groups (e.g. elderly people with cognitive or motor problems or certain conditions of medication intake), it is important for patients to consult their doctor who knows their medical history and condition. </p> <p><b>What should happen next?</b> </p> <p>Future research needs to compare eszopiclone with other sleep medications to help physicians and patients decide which of the available treatment options to prefer. In addition, sleep medications that are also well tolerated by elderly individuals and individuals with alcohol or drug problems need to be identified. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010703-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010703-sec-0128"></div> <h3 class="title" id="CD010703-sec-0129">Implications for practice</h3> <section id="CD010703-sec-0129"> <p>The review of 14 RCTs with 4732 participants showed significant effects of eszopiclone on primary and secondary sleep efficacy outcomes. Compared to placebo, eszopiclone was shown to reduce time to fall asleep by about 12 minutes and wake time after sleep onset by about 17 minutes, contributing to a more or less half an hour increase of total sleep time per night. Efficacy of eszopiclone on sleep has been shown to cover different age groups and insomnia types, including insomnia as a primary and comorbid condition. Evidence from two six‐month trials indicated that therapeutic benefits can be maintained over medium‐ to long‐term treatment periods. Participants taking eszopiclone may subjectively experience better functioning the next day than participants taking placebo, although the effect is likely to be small. Participants in the eszopiclone group reported more often unpleasant taste, dry mouth, somnolence, and dizziness. Discontinuation of eszopiclone after several weeks and months of treatment did not result in withdrawal symptoms, while rebound effects were occasionally reported, but not observed in the majority of RCTs. </p> <p>However, these implications for practice should not be made without refering to potential limitations in the quality and generalisability of evidence. First of all, due to the open‐label design of run‐out intervals (see <a href="#CD010703-sec-0119">Quality of the evidence</a>), the risk of rebound insomnia after the discontinuation of eszopiclone might be underestimated by some trials. In addition, the exclusion of certain participant groups, such as elderly participants with cognitive and psychomotor impairments or individuals with high dose or combined use from clinical trials, might limit the safety conclusions of the review (see <a href="#CD010703-sec-0118">Overall completeness and applicability of evidence</a>). </p> <p>The review suggests that in healthy individuals who use the drug as prescribed for a limited time, eszopiclone can be considered a safe and efficacious treatment for insomnia. Intermittent dosing or 'treatment as needed' might be an alternative to daily scheduled treatment, but the risk‐benefit profile has to assessed by future research (see <a href="#CD010703-sec-0130">Implications for research</a>). </p> </section> <h3 class="title" id="CD010703-sec-0130">Implications for research</h3> <section id="CD010703-sec-0130"> <p>The RCTs included in the review showed various methodological strengths, which might serve as standards for future research. Such standards include baseline comparisons in sleep indicators between study groups to prevent selection bias, and the monitoring of medication compliance and of concomitant drugs as a strategy to control the risk of performance bias. Comparisons between groups for daytime napping have been implemented in studies with elderly subjects only, but might be equally helpful to control compensatory sleep in all age group samples. The consideration of both types of outcomes, SOL and WASO, allows a simultaneous assessment of distinctive drug effects on sleep onset and sleep maintenance and the identification of potential shifts in the efficacy profile of a hypnotic drug. </p> <p>At the same time, a stricter adherence to methodological standards of reporting, as outlined in the CONSORT statement (<a href="./references#CD010703-bbs2-0199" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLOS Medicine2010;7(3):e1000251. ">Schulz 2010</a>), would help to remove prevailing doubts and uncertainties resulting from an incomplete description of methods used for sequence generation, allocation concealment, and blinding procedures. Moreover, eszopiclone`s specific taste properties, which can potentially reveal the identity of the medication to participants or investigators (see <a href="./references#CD010703-bbs2-0162" title="MoncrieffJ , WesselyS , HardyR . Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003012.pub2] ">Moncrieff 2004</a>), constitute the need to taste‐match placebo to the active comparator drug in future RCTs. Finally, single‐blind run‐out periods should be routinely applied after treatment discontinuation in hypnotic drug trials to allow a valid assessment of withdrawal and rebound effects, which in turn serve as indicators of chronic use and dependence (<a href="./references#CD010703-bbs2-0216" title="VoderholzerU , RiemannD , HornyakM , BackhausJ , FeigeB , BergerM , et al. A double‐blind, randomised and placebo‐controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience 2001;251(3):117‐23. ">Vorderholzer 2001</a>). </p> <p>Despite the wide range of methods and conditions considered in RCTs, some issues were left for future research. One of these concerns the relative effectiveness and safety of eszopiclone compared to other hypnotic drugs. While findings from RCTs comparing eszopiclone with placebo are applicable to the question: 'Can this intervention work?' (<a href="./references#CD010703-bbs2-0135" title="KrishnanJA , SchatzM , ApterAJ . A call for action: comparative effectiveness research in asthma. Journal of Allergy and Clinical Immunology2011;127(1):123‐7. ">Krishnan 2011</a>), and the therapeutic decision whether to use eszopiclone or not, it is the evidence from active‐controlled trials that clinicians refer to when deciding which of the available treatment options to prefer. </p> <p>A further unresolved problem concerns the identification of appropriate treatment strategies for participant subgroups with an increased vulnerability to adverse events. The exclusion of specific samples from RCTs, such as participants with substance use disorders, contrasts with the high occurrence of insomnia in these groups of individuals and the potential impact insomnia has on substance use. In participants with comorbid alcohol dependence ‐ a group of individuals known to often use alcohol for self‐medicating sleeping problems ‐ insomnia was not only shown to significantly determine the severity of alcohol problems, but also the risk of a relapse to drinking during alcohol recovery (<a href="./references#CD010703-bbs2-0060" title="ArnedtJT , ConroyDA , BrowerKJ . Treatment options for sleep disturbances during alcohol recovery. Journal of Addictive Diseases2007;26(4):41‐54. ">Arnedt 2007</a>; <a href="./references#CD010703-bbs2-0071" title="BrowerKJ , AldrichMS , RobinsonEA , ZuckerRA , GredenJF . Insomnia, self‐medication, and relapse to alcoholism. American Journal of Psychiatry2001;158:399–404. ">Brower 2001</a>; <a href="./references#CD010703-bbs2-0079" title="ConroyDA , Todd ArnedtJ , BrowerKJ , StrobbeS , ConsensF , HoffmannR , et al. Perception of sleep in recovering alcohol‐dependent patients with insomnia: relationship with future drinking. Alcoholism: Clinical and Experimental Research2006;30(12):1992‐9. ">Conroy 2006</a>; <a href="./references#CD010703-bbs2-0107" title="FosterJH , PetersTJ . Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcoholism: Clinical and Experimental Research1999;23(6):1044–51. ">Foster 1999</a>; <a href="./references#CD010703-bbs2-0133" title="KaplanKA , McQuaidJ , PrimichC , RosenlichtN . An evidence‐based review of insomnia treatment in early recovery. Journal of Addiction Medicine2014;8(6):389‐94. ">Kaplan 2014</a>). The exclusion of these participant subgroups from RCTs, a decision justified from a safety perspective, might bear the risk of adhering to higher risk treatments (<a href="./references#CD010703-bbs2-0073" title="BrunetteMF , NoordsyDL , XieH , DrakeRE . Benzodiazepine use and abuse among patients with severe mental illness and co‐occurring substance use disorders. Psychiatric Services2003;54(10):1395‐401. ">Brunette 2003</a>) or to treatments with unclear indications and effectiveness (<a href="./references#CD010703-bbs2-0108" title="FriedmannPD , HermanDS , FreedmanS , LemonSC , RamseyS , SteinMD . Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. Journal of Addictive Diseases2003;22(2):91‐103. ">Friedmann 2003</a>). </p> <p>In conclusion, to ensure that efficacy research meets the needs of every day clinical practice, relevant samples (e.g. elderly with impairments, individuals with substance use disorders) and treatment conditions (e.g. as‐needed dosing regimen; <a href="./references#CD010703-bbs2-0115" title='HajakG , BandelowB , ZulleyJ , PittrowD . "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia‐‐assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry2002;14(1):1‐7. '>Hajak 2002a</a>; <a href="./references#CD010703-bbs2-0116" title='Hajak , G . Zolpidem "as needed" versus continuous administration: Pan‐European study results. Sleep Med Rev2002;6(Suppl 1):21‐8. '>Hajak 2002b</a>), flexible strategies have to be included in high quality research. Available RCTs that consider longer treatment durations point in the right direction, while the conclusiveness of results might be increased by elaborate study designs to assess withdrawal and rebound effects. Such studies would not only provide credible answers to urgent questions, but might also serve as further examples illustrating that clinical relevance does not necessarily preclude internal validity. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010703-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010703-sec-0029"></div> <div class="table" id="CD010703-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eszopiclone for insomnia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Eszopiclone versus placebo for insomnia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with insomnia<br/> <b>Settings:</b> Outpatient<br/> <b>Intervention:</b> Eszopiclone </p> <p><b>Comparator:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Eszopiclone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sleep onset latency</b><br/> Participant reports. Scale from 30 to 540 minutes; </p> <p>fewer minutes equalled better outcome; CFB and double‐blind average values included</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sleep onset latency in the control groups was<br/> <b>20 to 65.7 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sleep onset latency in the intervention groups was<br/> <b>11.94 minutes lower</b><br/> (16.03 to 7.86 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2890<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wake time after sleep onset</b><br/> Participant reports. Scale from: 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean wake time after sleep onset ranged across control groups from<br/> <b>46 to 78.1 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean wake time after sleep onset in the intervention groups was<br/> <b>17.02 minutes lower</b><br/> (24.89 to 9.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2295<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebound insomnia ‐ sleep onset latency</b><br/> Scale from: 0 to 540 minutes.<br/> Follow‐up: 3 days (14 days); fewer minutes equalled better outcome; CFB were calculated by subtracting the mean average of the first three nights of the placebo run‐out period from initial scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the control group was<br/> <b>‐24.02 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the intervention groups was<br/> <b>17 minutes higher</b><br/> (4.29 lower to 38.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebound insomnia ‐ wake time after sleep onset</b><br/> Scale from: 0 to 540 minutes.<br/> Follow‐up: 3 days (14 days); fewer minutes equalled better outcome; CFB were calculated by subtracting the mean average of the first three nights of the placebo run‐out period from initial scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the control group was<br/> <b>‐22.15 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ wake time after sleep onset in the intervention groups was<br/> <b>6.71 minutes lower</b><br/> (21.25 lower to 7.83 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total sleep time</b><br/> Participant reports. Scale from: 300 to 840; more minutes equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total sleep time ranged across control groups from<br/> <b>324.8 to 382.2 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total sleep time in the intervention groups was<br/> <b>27.70 minutes higher</b><br/> (20.30 to 35.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2935<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Next‐day alertness</b><br/> Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean next‐day alertness ranged across control groups from<br/> <b>5.7 to 7.3 on a 11‐point Likert Scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean next‐day alertness in the intervention groups was<br/> <b>0.46 points higher</b><br/> (0.28 to 0.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2061<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Serious adverse events (as defined in the primary study)</b> <br/> Participant reports. Serious adverse events observed during double‐blind treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4289<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/> (‐1 to 19) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> We downgraded evidence for sleep efficacy outcomes and adverse events by one grade due to methodological limitations (omission of specific design features from trial reports; taste properties of eszopiclone potentially revealing the identity of medication).<br/> <sup>2</sup> Even though some inconsistency of results was shown for WASO, heterogeneity was mainly attributable to one trial (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), whose exclusion resulted into a I<sup>2</sup> reduction from 55% to 6%.<br/> <sup>3</sup> We downgraded evidence for rebound insomnia outcomes by two grades as five RCTs (with a duration &gt; two weeks) applied open‐label extensions, naturalistic follow‐ups or no follow‐up, which we did not consider appropriate to control bias effects </p> <p><sup>4</sup> We downgraded evidence for next‐day alertness assessed through subjective measures by two grades as it was expected to be rather the objective than the subjective measures of next‐day functioning that might determine the risk of harm, including injuries and accidents </p> <p><sup>CFB: Change from baseline</sup> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010703-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010703-sec-0030"></div> <section id="CD010703-sec-0031"> <h3 class="title" id="CD010703-sec-0031">Description of the condition</h3> <p>Affecting between 6% to 10% of the adult population in Western countries, insomnia is not only a psychological burden to the individual affected by the condition, but also a major public health issue (<a href="./references#CD010703-bbs2-0161" title="MoloneyME , KonradTR , ZimmerCR . The medicalisation of sleeplessness: a public health concern. American Journal of Public Health2011;101:1429–33. ">Moloney 2011</a>; <a href="./references#CD010703-bbs2-0165" title="MorinCM , LeBlancM , DaleyM , GrégoireJP , MéretteC . Epidemiology of insomnia: prevalence, self‐help treatments, consultations, and determinants of help‐seeking behaviours. Sleep Medicine2006;7:123‐30. ">Morin 2006</a>; <a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>; <a href="./references#CD010703-bbs2-0171" title="OhayonMM . Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews2002;6(2):97‐111. ">Ohayon 2002</a>; <a href="./references#CD010703-bbs2-0172" title="OhayonMM , ReynoldsCF3rd . Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM‐IV and the International Classification of Sleep Disorders (ICSD). Sleep Medicine2009;10(9):952‐60. ">Ohayon 2009</a>; <a href="./references#CD010703-bbs2-0186" title="RothT , RoehrsT . Insomnia: epidemiology, characteristics, and consequences. Clinical Cornerstone2003;5(3):5‐15. ">Roth 2003</a>). Complaints increase with age and are twice as prevalent in women than in men (<a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>). </p> <p>The predominant symptom of insomnia is difficulty initiating sleep (sleep‐onset insomnia), maintaining sleep (sleep‐maintenance insomnia) or early morning awakening with inability to return to sleep (<a href="./references#CD010703-bbs2-0182" title="RiemannD , NissenC , PalaginiL , OtteA , PerlisML , SpiegelhalderK . The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurolology2015;14(5):547‐58. ">Riemann 2015</a>). According to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) (<a href="./references#CD010703-bbs2-0058" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM‐5. 5th Edition. Washington DC: American Psychiatric Publishing, 2013. ">American Psychiatric Association 2013</a>), and the third edition of the International Classification of Sleep Disorders (ICSD‐3) (<a href="./references#CD010703-bbs2-0057" title="American Academy of SleepMedicine . International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD‐3. 3nd. Chicago: American Academy of Sleep Medicine, 2014. ">American Academy of Sleep Medicine 2014</a>), dissatisfaction with sleep quantity or quality has to occur at least three nights per week over at least three months to be diagnosed as chronic insomnia. In addition, diagnosis of insomnia disorder requires that sleep problems occur despite adequate opportunity for sleep and cause at least one related daytime impairment, affecting social, occupational, or other important areas of functioning. </p> <p>Insomnia criteria in the DSM‐5 (<a href="./references#CD010703-bbs2-0058" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM‐5. 5th Edition. Washington DC: American Psychiatric Publishing, 2013. ">American Psychiatric Association 2013</a>), and ICSD‐3 (<a href="./references#CD010703-bbs2-0057" title="American Academy of SleepMedicine . International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD‐3. 3nd. Chicago: American Academy of Sleep Medicine, 2014. ">American Academy of Sleep Medicine 2014</a>) differ from previous classifications by considering frequency criteria and by increasing duration of the condition from one to three months. However, the most fundamental change to former definitions is that primary insomnia and secondary insomnia are not considered as different conditions anymore, but rather as a common category for insomnia disorder. Since causal attribution labels are removed now, insomnia disorder can be recognised as a condition requiring clinical attention irrespective of the presumed underlying causes (<a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>; <a href="./references#CD010703-bbs2-0181" title="RiemannD , BaglioniC , FeigeB , SpiegelhalderK . Insomnia ‐ state of the science. Der Nervenarzt2014;85(1):43‐9. ">Riemann 2014</a>). </p> <p>Various models of insomnia refer to a common framework proposed by <a href="./references#CD010703-bbs2-0208" title="SpielmanAJ , GlovinskyPB . The varied nature of insomnia. In: HauriP editor(s). Case Studies in Insomnia. New York: Plenum Press, 1991:1‐15. ">Spielman 1991</a>, distinguishing between predisposing, precipitating, and perpetuating factors. While predisposing factors, such as maladaptive coping stress strategies, cognitive‐emotional hyperarousal and older age, make individuals more vulnerable to sleeping problems (<a href="./references#CD010703-bbs2-0101" title="Fernández‐MendozaJ , Vela‐BuenoA , VgontzasAN , Ramos‐PlatónMJ , Olavarrieta‐BernardinoS , BixlerEO , et al. Cognitive‐emotional hyperarousal as a premorbid characteristic of individuals vulnerable to insomnia. Psychosomatic Medicine2010;72(4):370‐403. ">Fernández‐Mendoza 2010</a>), increased life‐stress, irregular sleep habits, and poor sleep hygiene further precipitate their occurrence (<a href="./references#CD010703-bbs2-0064" title="BastienCH , VallièresA , MorinCM . Precipitating factors of insomnia. Behavioral Sleep Medicine2004;2(1):50‐62. ">Bastien 2004</a>). If sleep is repeatedly disturbed, a further perpetuation of the problem results from the selective attention directed towards the inability to fall asleep, creating a vicious cycle that often leads to chronicity. The neurocognitive model of insomnia (<a href="./references#CD010703-bbs2-0175" title="PerlisML , GilesDE , MendelsonWB , BootzinRR , WyattJK . Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. Journal of Sleep Research1997;6:179‐88. ">Perlis 1997</a>; <a href="./references#CD010703-bbs2-0075" title="BuysseDJ , GermainA , HallM , MonkTH , NofzingerEA . A neurobiological model of insomnia. Drug Discovery Today: Disease Models2011;8(4):129‐37. ">Buysse 2011</a>) emphasises the role of hyperarousal, including an increased level of somatic, cognitive and cortical activity, which is enforced through classical conditioning and which promotes abnormal levels of sensory and information processing, thought to render the insomniac individual especially vulnerable to perturbation by environmental or other stimuli (<a href="./references#CD010703-bbs2-0180" title="RiemannD , KloepferC , BergerM . Functional and structural brain alterations in insomnia: implications for pathophysiology. European Journal of Neuroscience2009;29(9):1754‐60. ">Riemann 2009</a>). The inhibition model developed by <a href="./references#CD010703-bbs2-0096" title="EspieCA . Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annual Review of Psychology2002;53:215‐43. ">Espie 2002</a>, conceptualises insomnia as the failure to inhibit wakefulness rather than the inability to induce sleep and underscores the originally functional role of wakefulness in the presence of stressors. If a 'threat' is not eliminated, attention is increasingly focused on sleep and motivational processes, including the conscious intent to fall asleep. The attention‐intention‐effort pathway model (<a href="./references#CD010703-bbs2-0097" title="EspieCA , BroomfieldNM , MacMahonKM , MacpheeLM , TaylorLM . The attention‐intention‐effort pathway in the development of psychophysiologic insomnia: a theoretical review. Sleep Medicine Reviews2006;10(4):215‐45. ">Espie 2006</a>), explains how these processes interfere with the otherwise automatic response of inhibiting wakefulness. Current research outlines the interaction between genetics, personality, coping styles and sleep‐interfering processes like increased stress‐reactivity and hyperarousal (<a href="./references#CD010703-bbs2-0120" title="HarveyCJ , GehrmanP , EspieCA . Who is predisposed to insomnia: a review of familial aggregation, stress‐reactivity, personality and coping style. Sleep Med Rev2014;18(3):237‐47. ">Harvey 2018</a>; <a href="./references#CD010703-bbs2-0173" title="PalaginiL , BiberK , RiemannD . The genetics of insomnia‐‐evidence for epigenetic mechanisms?. Sleep Med Rev2014;18(3):225‐35. ">Palagini 2014</a>). It is hypothesized that epigenetic mechanisms involved in both sleep regulation and brain‐stress response persist into adulthood through effects on brain plasticity (<a href="./references#CD010703-bbs2-0173" title="PalaginiL , BiberK , RiemannD . The genetics of insomnia‐‐evidence for epigenetic mechanisms?. Sleep Med Rev2014;18(3):225‐35. ">Palagini 2014</a>). </p> <p>Insomnia has traditionally been considered as a symptom of another disease, rather than a discrete disorder (<a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>). Even though insomnia is often associated with psychiatric and medical conditions that contribute to sleep disturbance in diverse ways (<a href="./references#CD010703-bbs2-0134" title="KatzDA , McHorneyCA . Clinical correlates of insomnia in patients with chronic illness. Archives of Internal Medicine1998;158(10):1099–1107. ">Katz 1998</a>; <a href="./references#CD010703-bbs2-0138" title="KrystalAD , McCallWV , FavaM , JoffeH , SoaresCN , HuangH , et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. The Primary Care Companion for CNS Disorders2012;14(4):doi: 10.4088/PCC.11m01296. [DOI: 10.4088/PCC.11m01296] ">Krystal 2012b</a>), it is now conceptualised as a discrete disorder and as an independent risk factor for further medical and psychiatric problems (<a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>). Insomnia is known to increase the risk for depression and substance use disorders (<a href="./references#CD010703-bbs2-0099" title="FalcónE , McClungCA . A role for the circadian genes in drug addiction. Neuropharmacology2009;56(1):91‐6. ">Falcón 2009</a>; <a href="./references#CD010703-bbs2-0131" title="JohnsonEO , BreslauN . Sleep problems and substance use in adolescence.. Drug and Alcohol Dependence2001;64(1):1‐7. ">Johnson 2001</a>; <a href="./references#CD010703-bbs2-0179" title="RiemannD . Insomnia and comorbid psychiatric disorders. Sleep Medicine2007;8(4):15‐20. ">Riemann 2007</a>; <a href="./references#CD010703-bbs2-0183" title="RoaneBM , TaylorDJ . Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep2008;31(10):1351‐6. ">Roane 2008</a>), and coronary heart disease (e.g. <a href="./references#CD010703-bbs2-0077" title="CappuccioFP , CooperD , D'EliaL , StrazzulloP , MillerMA . Sleep duration predicts cardiovascular outcomes: a systematic review and meta‐analysis of prospective studies. European Heart Journal2011;32(12):1484‐92. ">Cappuccio 2011</a>; <a href="./references#CD010703-bbs2-0102" title="FerrieJE , ShipleyMJ , CappuccioFP , BrunnerE , MillerMA , KumariM , et al. A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep2007;30(12):1659‐66. ">Ferrie 2007</a>; <a href="./references#CD010703-bbs2-0144" title="LiY , ZhangX , WinkelmanJW , RedlineS , HuFB , StampferM , et al. Association between insomnia symptoms and mortality: a prospective study of U.S. men. Circulation2014;129(7):737‐46. ">Li 2014</a>; <a href="./references#CD010703-bbs2-0174" title="ParthasarathyS , VasquezMM , HalonenM , BootzinR , QuanSF , MartinezFD , et al. Persistent insomnia is associated with mortality risk. American Journal of Medicine2015;128(3):268‐75. ">Parthasaraty 2015</a>; <a href="./references#CD010703-bbs2-0206" title="SofiF , CesariF , CasiniA , MacchiC , AbbateR , GensiniG . Insomnia and risk of cardiovascular disease: a meta‐analysis. European Journal of Preventive Cardiology2014;21(1):57‐64. ">Sofi 2014</a>; <a href="./references#CD010703-bbs2-0221" title="WinkelmanJW . Insomnia [Insomnia Disorder]. N Engl J Med2015;373(15):1437‐44. ">Winkelman 2015</a>; <a href="./references#CD010703-bbs2-0224" title="XiaoQ , KeadleSK , HollenbeckAR , MatthewsCE . Sleep duration and total and cause‐specific mortality in a large US cohort: interrelationships with physical activity, sedentary behavior, and body mass index. American Journal of Epidemiology2014;180(10):997‐1006. ">Xiao 2014</a>). Besides causing psychological distress, insomnia leads to next‐day cognitive and psychomotor impairments (<a href="./references#CD010703-bbs2-0106" title="Fortier‐BrochuE , Beaulieu‐BonneauS , IversH , MorinCM . Insomnia and daytime cognitive performance: a meta‐analysis. Sleep Medicine Reviews2012;16(1):83‐94. ">Fortier‐Brochu 2012</a>; <a href="./references#CD010703-bbs2-0202" title="ShekletonJA , RogersNL , RajaratnamSM . Searching for the daytime impairments of primary insomnia. Sleep Medicine Reviews2010;14(1):47‐60. ">Shekleton 2010</a>), irritability, and decreased job performance (<a href="./references#CD010703-bbs2-0159" title="MetlaineA , LegerD , ChoudatD . Socioeconomic impact of insomnia in working populations. Industrial Health2005;43(1):11‐9. ">Metlaine 2005</a>), and has been shown to reduce life quality (<a href="./references#CD010703-bbs2-0185" title="RosekindMR , GregoryKB . Insomnia risks and costs: health, safety, and quality of life. American Journal of Managed Care2010;16(8):617‐26. ">Rosekind 2010</a>; <a href="./references#CD010703-bbs2-0225" title="ZammitGK , WeinerJ , DamatoN , SillupGP , McMillanCA . Quality of life in people with insomnia. Sleep1999;22(2):379‐85. ">Zammit 1999</a>), and longevity (<a href="./references#CD010703-bbs2-0188" title="RothT . Sleep duration, insomnia and longevity. Sleep Medicine2009;10(10):1071‐2. ">Roth 2009a</a>). Untreated insomnia does usually not remit with time (<a href="./references#CD010703-bbs2-0059" title="AngstJ , VollrathM , KochR , Dobler‐MikolaA . The Zurich Study. VII. Insomnia: symptoms, classification and prevalence. European Archives of Psychiatry and Neurological Sciences1989;238(5‐6):285‐93. ">Angst 1989</a>; <a href="./references#CD010703-bbs2-0142" title="LeshnerA . NIH State‐of‐the‐Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consensus and State‐of‐the‐Science Statements. 2005; Vol. 22:1‐30. ">Leshner 2005</a>), underscoring the need for effective and safe treatment interventions. </p> </section> <section id="CD010703-sec-0032"> <h3 class="title" id="CD010703-sec-0032">Description of the intervention</h3> <p>Insomnia is still under‐recognised and often goes untreated (<a href="./references#CD010703-bbs2-0166" title="MorinCM , BencaR . Chronic insomnia. Lancet2012;24(379):1129‐41. ">Morin 2012</a>). Even though often recommended as first‐line treatments for chronic insomnia (<a href="./references#CD010703-bbs2-0114" title="HajakG , Muller‐PopkesK , RiemannD , MayerG , LauerC . Psychological, psychotherapeutic and other non‐pharmacologic forms of therapy in treatment of insomnia. Fortschritte der Neurologie‐Psychiatrie1997;65(3):133‐44. ">Hajak 1997</a>; <a href="./references#CD010703-bbs2-0177" title="RamakrishnanK , ScheidDC . Treatment options for insomnia. American Family Physician2007;76(4):517‐26. ">Ramakrishnan 2007</a>; <a href="./references#CD010703-bbs2-0214" title="vanStratenA , van derZweerdeT , KleiboerA , CuijpersP , MorinCM , LanceeJ . Cognitive and behavioral therapies in the treatment of insomnia: A meta‐analysis. Sleep Med Rev2018;38:3‐16. ">van Straten 2018</a>), non‐pharmacological treatment strategies, including cognitive behavioural therapy (CBT), are rarely used in clinical practice (<a href="./references#CD010703-bbs2-0076" title="CapeJ , LeibowitzJ , WhittingtonC , EspieCA , PillingS . Group cognitive behavioural treatment for insomnia in primary care: a randomised controlled trial. Psychological Medicine2015;16:1‐11. ">Cape 2015</a>). Benzodiazepine hypnotics are effective for short‐term treatment of insomnia (<a href="./references#CD010703-bbs2-0074" title="BuscemiN , VandermeerB , FriesenC , BialyL , TubmanM , OspinaM , et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta‐analysis of RCTs. Journal of General Internal Medicine2007;22(9):1335‐50. ">Buscemi 2007</a>), but carry the risk of rebound insomnia, withdrawal symptoms, dependence (<a href="./references#CD010703-bbs2-0061" title="BallengerJC . Benzodiazepine receptor agonists and antagonists. In: SadockVA , SadockBJ , KaplanHI editor(s). Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry. 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2000. ">Ballenger 2000</a>; <a href="./references#CD010703-bbs2-0139" title="LaderMH . Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. European Neuropsychopharmacology1999;9(Suppl 6):399‐405. ">Lader 1999</a>; <a href="./references#CD010703-bbs2-0189" title="Royal College of Psychiatrists. Benzodiazepines: risks, benefits or dependence. A re‐evaluation. Council Report CR59; 1997; London1997. ">Royal College of Psychiatrists 1997</a>), and next‐day hangover effects, responsible for traffic and machine operation accidents (<a href="./references#CD010703-bbs2-0062" title="BarboneF , McMahonAD , DaveyPG , MorrisAD . Association of road‐traffic accidents with benzodiazepine use. Lancet1998;352(9137):1331‐6. ">Barbone 1998</a>), self injuries and hip fractures, the latter commonly seen in elderly patients (<a href="./references#CD010703-bbs2-0069" title="BoltonJM , MetgeC , LixL , PriorH , SareenJ , LeslieWD . Fracture risk from psychotropic medications: a population‐based analysis. Journal of Clinical Psychopharmacology2008;28(4):384‐91. ">Bolton 2008</a>; <a href="./references#CD010703-bbs2-0222" title="WoolcottJC , RichardsonKJ , WiensMO , PatelB , MarinJ , KhanKM , et al. Meta‐analysis of the impact of 9 medication classes on falls in elderly persons. Archives of Internal Medicine2009;169(21):1952‐60. ">Woolcott 2009</a>). </p> <p>In the 1980s and early 1990s, a new group of hypnotic agents, known as new generation hypnotics, non‐benzodiazepine hypnotics, benzodiazepine receptor agonists or 'z‐drugs', were introduced to the markets. Meanwhile, zopiclone, zolpidem, zaleplon and eszopiclone, four different non‐benzodiazepine hypnotic compounds, have been developed and introduced as insomnia therapies (<a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). Eszopiclone is a pyrrolo pyrazine derivative of the cyclopyrrolone class and the (S)‐enantiomer of racemic zopiclone. While racemic zopiclone was approved in 1986 for the European market and used as a hypnotic in many countries for more than two decades without being licensed in the USA, eszopiclone (Lunesta) received the US Food and Drug Administration (FDA) approval in December 2004. In the USA, eszopiclone is approved for short‐ or long‐term treatment of sleep onset and sleep maintenance insomnia in adults and is marketed in 1 mg, 2 mg and 3 mg film‐coated tablets. To date, eszopiclone is not available in Europe as the originator of Lunesta, Sepracor Pharmaceuticals Ltd, withdrew the application for a centralised marketing authorisation for Lunivia to the European Medicines Agency (EMEA) in 2009 (<a href="./references#CD010703-bbs2-0098" title="European Medicines Agency. Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone). www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000083.jsp (accessed 16 February 2015). ">European Medicines Agency 2009</a>). </p> <p>As shown by animal studies, the (S)‐enantiomer of racemic zopiclone is the one of two stereoisomers that mainly mediates its hypnotic effects (<a href="./references#CD010703-bbs2-0158" title="MeltonST , WoodJM , KirkwoodCK . Eszopiclone for insomnia. Annals of Pharmacotherapy2005;39(10):1659‐66. ">Melton 2005</a>; <a href="./references#CD010703-bbs2-0113" title="HairPI , McCormackPL , CurranMP . Eszopiclone: a review of its use in the treatment of insomnia. Drugs2008;68(10):1415‐34. ">Hair 2008</a>). Accordingly, recommended clinical dosages are about 50% lower for eszopiclone compared to racemic zopiclone (<a href="./references#CD010703-bbs2-0111" title="GreenblattDJ , ZammitGK . Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opinion in Drug Metabolism and Toxicology2012;8(12):1609‐18. ">Greenblatt 2012</a>). The recommended starting dose for eszopiclone was initially 2 mg in non‐elderly adults and 1 mg for elderly patients (<a href="./references#CD010703-bbs2-0201" title="Prescribing information. Lunesta® (eszopiclone). Sepracor Inc; Marlborough MA. ">Sepracor 2004 [pers comm]</a>; <a href="./references#CD010703-bbs2-0113" title="HairPI , McCormackPL , CurranMP . Eszopiclone: a review of its use in the treatment of insomnia. Drugs2008;68(10):1415‐34. ">Hair 2008</a>) and lowered to 1 mg for men and women of all age groups by a current FDA safety alert (<a href="./references#CD010703-bbs2-0105" title="Food , DrugAdministration . Eszopiclone containing sleep aids: drug safety communication ‐ can cause next‐day impairment. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm397536.htm (accessed 12 March 2015). ">Food and Drug Administration 2015</a>) due to the risk of next‐day impairments as shown in a randomised, double‐blind cross‐over study (<a href="./references#CD010703-bbs2-0017" title="BoyleJ , GroegerJA , PaskaW , CooperJA , RockettC , JonesS , et al. A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. Journal of Clinical Psychopharmacology2012;32(5):704‐9. ">Boyle 2012</a>). The maximum recommended dose of eszopiclone is 3 mg in non‐elderly and 2 mg in elderly subjects (<a href="./references#CD010703-bbs2-0148" title="Lunesta® (eszopiclone) package insert. Sepracor Inc (Sunovion Pharmaceuticals): Marlborough (MA)2004. ">Lunesta 2004 [pers comm]</a>). Eszopiclone is rapidly absorbed (maximum plasma concentration (T<sub>max</sub> ˜ one hour), has a relatively long elimination half‐life time (t<sub>1/2</sub>˜ six hours) compared to other non‐benzodiazepine hypnotic compounds, and was shown not to accumulate after multiple once‐daily administration (<a href="./references#CD010703-bbs2-0113" title="HairPI , McCormackPL , CurranMP . Eszopiclone: a review of its use in the treatment of insomnia. Drugs2008;68(10):1415‐34. ">Hair 2008</a>; <a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). Eszopiclone is known to cause a bitter or metallic taste, while there is no convincing explanation for this effect (<a href="./references#CD010703-bbs2-0111" title="GreenblattDJ , ZammitGK . Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opinion in Drug Metabolism and Toxicology2012;8(12):1609‐18. ">Greenblatt 2012</a>). The drug is classified as a Schedule IV controlled substance (<a href="./references#CD010703-bbs2-0167" title="NajibJ . Eszopiclone, a nonbenzodiazepine sedative‐hypnotic agent for the treatment of transient and chronic insomnia. Clinical Therapeutics2006;28(4):491‐516. ">Najib 2006</a>). </p> </section> <section id="CD010703-sec-0033"> <h3 class="title" id="CD010703-sec-0033">How the intervention might work</h3> <p>Similar to benzodiazepines, non‐benzodiazepine hypnotics develop their sedative properties through activity at the gamma‐aminobutyric acid‐A (GABA‐A) receptor, whose endogenous ligand, GABA, is the major inhibitory neurotransmitter in the central nervous system, involved in anxiolysis, sedation, seizure suppression and muscle relaxation (<a href="./references#CD010703-bbs2-0065" title="BatesonAN . The benzodiazepine site of the GABAA receptor: an old target with new potential?. Sleep Medicine2004;5(1):9‐15. ">Bateson 2004</a>; <a href="./references#CD010703-bbs2-0190" title="RudolphU , KnoflachF . Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Reviews Drug Discovery2011;10(9):685‐97. ">Rudolph 2011</a>). The GABA‐A receptor is composed of five protein subunits and at least 19 distinct subunit isoforms, mediating different behavioural and pharmacological responses (<a href="./references#CD010703-bbs2-0084" title="DolderC , NelsonM , McKinseyJ . Use of non‐benzodiazepine hypnotics in the elderly: are all agents the same?. CNS Drugs2007;21(5):389‐405. ">Dolder 2007</a>; <a href="./references#CD010703-bbs2-0086" title="DroverDR . Comparative pharmacokinetics and pharmacodynamics of short‐acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clinical Pharmacokinetics2004;43(4):227‐38. ">Drover 2004</a>; <a href="./references#CD010703-bbs2-0089" title="DündarY , BolandA , StroblJ , DoddS , HaycoxA , BagustA , et al. Newer hypnotic drugs for the short‐term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment2004;8(24):iii‐x, 1‐125. ">Dündar 2004b</a>; <a href="./references#CD010703-bbs2-0203" title="SieghartW . Structure, pharmacology, and function of GABAA receptor subtypes. Advances in Pharmacology2006;54:231‐63. ">Sieghart 2006</a>). Alpha 1 subunits of the GABA‐A receptor are thought to be mainly responsible for the mediation of sedative drug effects, alpha 2 and alpha 3 subunits for anxiolytic and antidepressant drug activities, and alpha 5 receptor subunits for cognitive effects including memory and learning (<a href="./references#CD010703-bbs2-0147" title="Lingford‐HughesA , HumeSP , FeeneyA , HiraniE , OsmanS , CunninghamVJ , et al. Imaging the GABA‐benzodiazepine receptor subtype containing the alpha 5‐subunit in vivo with (11C)Ro15 4513 positron emission tomography. Journal of Cerebral Blood Flow and Metabolism2002;22:878–88. ">Lingford‐Hughes 2002</a>; <a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). While benzodiazepines modulate different subunits of the GABA‐A receptor, the non‐benzodiazepine hypnotics, zaleplon and zolpidem, bind more selectively to the alpha 1‐containing receptor subtypes responsible for sedation (<a href="./references#CD010703-bbs2-0163" title="MontiJM , Pandi‐PerumalSR . Eszopiclone: its use in the treatment of insomnia. Neuropsychiatric Disease and Treatment2007;3(4):441‐53. ">Monti 2007</a>). Accordingly, non‐benzodiazepine hypnotics are assumed to produce an advantageous clinical profile compared to benzodiazepines, particularly with respect to residual effects, tolerance and dependence (<a href="./references#CD010703-bbs2-0086" title="DroverDR . Comparative pharmacokinetics and pharmacodynamics of short‐acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clinical Pharmacokinetics2004;43(4):227‐38. ">Drover 2004</a>; <a href="./references#CD010703-bbs2-0104" title="FollesaP , MancusoL , BiggioF , CagettiE , FrancoM , TrapaniG , et al. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long‐term exposure to, zaleplon or zolpidem. Neuropharmacology2002;42(2):191‐8. ">Follesa 2002</a>). The cyclopyrrolone derivates, zopiclone and eszopiclone, are not receptor subtype‐specific, but zopiclone has shown to have high affinity binding sites in the cerebral cortex, hippocampus and cerebellum, and greater affinity for alpha 1 and alpha 2 subunits than benzodiazepines (<a href="./references#CD010703-bbs2-0167" title="NajibJ . Eszopiclone, a nonbenzodiazepine sedative‐hypnotic agent for the treatment of transient and chronic insomnia. Clinical Therapeutics2006;28(4):491‐516. ">Najib 2006</a>). Like racemic (R,S) zopiclone, eszopiclone shows relatively high binding affinity for the alpha 1, but also for the 2 and 3 receptor subtype, which might indicate that eszopiclone has both hypnotic and anxiolytic effects (<a href="./references#CD010703-bbs2-0111" title="GreenblattDJ , ZammitGK . Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opinion in Drug Metabolism and Toxicology2012;8(12):1609‐18. ">Greenblatt 2012</a>; <a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). </p> <p>Further differences in the clinical effects of non‐benzodiazepine hypnotics are assumed to be associated with their unique pharmacokinetic profiles, including the bioavailability of the drug, the volume of distribution and the elimination half‐life time (<a href="./references#CD010703-bbs2-0085" title="DroverD , LemmensH , NaiduS , CevallosW , DarwishM , StanskiD . Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics2000;22(12):1443‐61. ">Drover 2000</a>). Like zopiclone, eszopiclone has a longer half‐life time than the non‐benzodiazepine hypnotic compounds, zaleplon or zolpidem, and is thus expected to be particularly useful for the treatment of sleep‐maintenance insomnia (<a href="./references#CD010703-bbs2-0085" title="DroverD , LemmensH , NaiduS , CevallosW , DarwishM , StanskiD . Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics2000;22(12):1443‐61. ">Drover 2000</a>). The prolonged elimination time of eszopiclone may, on the other hand, increase the risk of next‐day impairments (<a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). Considering the rapid onset of action, eszopiclone appears to have an improved pharmacokinetic profile compared to racemic zopiclone, presumably due to the absence of the confounding effects of (R)‐zopiclone, resulting in a slightly faster onset of action and a reduced individual variability in response (<a href="./references#CD010703-bbs2-0111" title="GreenblattDJ , ZammitGK . Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. Expert Opinion in Drug Metabolism and Toxicology2012;8(12):1609‐18. ">Greenblatt 2012</a>; <a href="./references#CD010703-bbs2-0170" title="NuttDJ , StahlSM . Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology2010;24(11):1601‐12. ">Nutt 2010</a>). Levels of (S)‐desmethylzopiclone, one of the active metabolites of eszopiclone and zopiclone, are lower than those seen after an equivalent effective dose of racemic zopiclone, suggesting a reduced risk of residual effects for the pure active enantiomer (<a href="./references#CD010703-bbs2-0072" title="BrunelloN , BetticaP , AmatoD , MaierG , NuttD . Pharmacokinetics of (S)‐zopiclone and (S)‐desmethylzopiclone following dosing with zopiclone and eszopiclone. Neuropsychopharmacology2008;18:581. ">Brunello 2008</a>). </p> </section> <section id="CD010703-sec-0034"> <h3 class="title" id="CD010703-sec-0034">Why it is important to do this review</h3> <p>Use of hypnotic drugs increased over the past decades, with a striking rise in prescriptions for non‐benzodiazepine hypnotics (<a href="./references#CD010703-bbs2-0068" title="BertischSM , HerzigSJ , WinkelmanJW , BuettnerC . National use of prescription medications for insomnia: NHANES 1999‐2010. Sleep2014;37(2):343‐9. ">Bertisch 2014</a>). Being marketed as just as effective as benzodiazepines, while being safer and having a lower risk for abuse and dependence, non‐benzodiazepine hypnotics have meanwhile replaced benzodiazepines as the most commonly prescribed hypnotic drugs and emerged as the first‐line drugs for insomnia treatment (<a href="./references#CD010703-bbs2-0095" title="ErmanMK . Therapeutic options in the treatment of insomnia. Journal of Clinical Psychiatry2005;66(9):18‐23. ">Erman 2005</a>; <a href="./references#CD010703-bbs2-0121" title="HauskenAM , FuruK , SkurtveitS , EngelandA , BramnessJG . Starting insomnia treatment: the use of benzodiazepines versus z‐hypnotics. A prescription database study of predictors. European Journal of Clinical Pharmacology2009;65(3):295‐301. ">Hausken 2009</a>; <a href="./references#CD010703-bbs2-0124" title="HoffmannF , ScharffetterW , GlaeskeG . Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007. Der Nervenarzt2009;80(5):578‐83. ">Hoffmann 2009</a>; <a href="./references#CD010703-bbs2-0168" title="National Prescribing Service. Addressing hypnotic medicines use in primary care. www.nps.org.au/health_professionals/publications/nps_news/current/nps_news_672010. ">NHS Prescribing Service 2010</a>; <a href="./references#CD010703-bbs2-0204" title="SiriwardenaAN , QureshiMZ , DyasJV , MiddletonH , OrnerR . Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. British Journal of General Practice2008;58(551):417‐22. ">Siriwardena 2008</a>). </p> <p>At the same time, there is an increasing controversy about the safety profile of non‐benzodiazepine hypnotics (<a href="./references#CD010703-bbs2-0078" title="Cimolai , N . Zopiclone. Is it a pharmacologic agent for abuse?. Canadian Family Physician2007;53:2124‐9. ">Cimolai 2007</a>). Various reviews of preclinical and clinical evidence (<a href="./references#CD010703-bbs2-0086" title="DroverDR . Comparative pharmacokinetics and pharmacodynamics of short‐acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clinical Pharmacokinetics2004;43(4):227‐38. ">Drover 2004</a>; <a href="./references#CD010703-bbs2-0088" title="DündarY , DoddS , StroblJ , BolandA , DicksonR , WalleyT . Comparative efficacy of newer hypnotic drugs for the short‐term management of insomnia: a systematic review and meta‐analysis. Human Psychopharmacology2004;19(5):305‐22. ">Dündar 2004a</a>; <a href="./references#CD010703-bbs2-0089" title="DündarY , BolandA , StroblJ , DoddS , HaycoxA , BagustA , et al. Newer hypnotic drugs for the short‐term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment2004;8(24):iii‐x, 1‐125. ">Dündar 2004b</a>; <a href="./references#CD010703-bbs2-0164" title="MontplaisirJ , HawaR , MollerH , MorinC , FortinM , MatteJ , et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Human Psychopharmacology2003;18(1):29‐38. ">Montplaisir 2003</a>; <a href="./references#CD010703-bbs2-0226" title="ZammitG . Comparative tolerability of newer agents for insomnia. Drug Safety2009;32(9):735‐48. ">Zammit 2009</a>), post‐marketing surveillance studies (<a href="./references#CD010703-bbs2-0081" title="DelahayeC , FerrandB , PieddeloupC , MuschB . Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice. International Clinical Psychopharmacology1990;5 Suppl(2):131‐8. ">Delahaye 1990</a>; <a href="./references#CD010703-bbs2-0129" title="JaffeJH1 , BloorR , CromeI , CarrM , AlamF , SimmonsA , et al. A post‐marketing study of relative abuse liability of hypnotic sedative drugs. Addiction2004;99(2):165‐73. ">Jaffe 2004</a>), and reviews of case study reports (<a href="./references#CD010703-bbs2-0117" title="HajakG , MüllerWE , WittchenHU , PittrowD , KirchW . Abuse and dependence potential for the non‐benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction2003;98(10):1371‐8. ">Hajak 2003</a>; <a href="./references#CD010703-bbs2-0139" title="LaderMH . Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. European Neuropsychopharmacology1999;9(Suppl 6):399‐405. ">Lader 1999</a>; <a href="./references#CD010703-bbs2-0207" title="SoykaM , BottlenderR , MöllerHJ . Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry2000;33(4):138‐41. ">Soyka 2000</a>) confirm the advantages of non‐benzodiazepine hypnotics in terms of next‐day impairments and their potential for abuse and dependence. Double‐blind studies examining the subjective effects of zolpidem in drug‐naive individuals (<a href="./references#CD010703-bbs2-0145" title="LicataSC , PenetarDM , DunlapS , LukasSE . A therapeutic dose of zolpidem has limited abuse‐like effects in drug‐naïve females: a pilot study. European Journal of Pharmacology2008;598(1‐3):64‐7. ">Licata 2008</a>) and assessing polysomnographic withdrawal effects of zopiclone and zolpidem in healthy subjects (<a href="./references#CD010703-bbs2-0216" title="VoderholzerU , RiemannD , HornyakM , BackhausJ , FeigeB , BergerM , et al. A double‐blind, randomised and placebo‐controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience 2001;251(3):117‐23. ">Vorderholzer 2001</a>) have found a low risk of tolerance and dependency for these drugs, if taken in recommended doses. Further studies and reviews, likewise referring to patient surveys and pharmacovigilance data, rate the abuse liability of non‐benzodiazepine hypnotics as comparable to that of benzodiazepine hypnotics (e.g. <a href="./references#CD010703-bbs2-0124" title="HoffmannF , ScharffetterW , GlaeskeG . Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007. Der Nervenarzt2009;80(5):578‐83. ">Hoffmann 2009</a>; <a href="./references#CD010703-bbs2-0125" title="HoffmannF , GlaeskeG . Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012. Der Nervenarzt2014;85(11):1402‐9. ">Hoffmann 2014</a>; <a href="./references#CD010703-bbs2-0204" title="SiriwardenaAN , QureshiMZ , DyasJV , MiddletonH , OrnerR . Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. British Journal of General Practice2008;58(551):417‐22. ">Siriwardena 2008</a>; <a href="./references#CD010703-bbs2-0215" title="Victorri‐VigneauC , GérardinM , RousseletM , GuerlaisM , Grall‐BronnecM , JollietP . An update on zolpidem abuse and dependence. Journal of Addictive Diseases2014;33(1):15‐22. ">Victorri‐Vigneau 2014</a>). Parasomnia, amnesia, and hallucinations have been documented as adverse events of zolpidem (<a href="./references#CD010703-bbs2-0066" title="Ben‐HamouM , MarshallNS , GrunsteinRR , SainiB , FoisRA . Spontaneous adverse event reports associated with zolpidem in Australia 2001‐2008. Journal of Sleep Research2011;20(4):559‐68. ">Ben‐Hamou 2011</a>) and there is evidence that eszopiclone can cause euphoria and hallucination if taken in elevated doses (<a href="./references#CD010703-bbs2-0196" title="ScharfM . Eszopiclone for the treatment of insomnia. Expert Opinion in Pharmacotherapy2006;7(3):345‐56. ">Scharf 2006</a>; <a href="./references#CD010703-bbs2-0163" title="MontiJM , Pandi‐PerumalSR . Eszopiclone: its use in the treatment of insomnia. Neuropsychiatric Disease and Treatment2007;3(4):441‐53. ">Monti 2007</a>). </p> <p>In addition, current evidence indicates that the risk of the non‐benzodiazepine hypnotic drugs in causing next‐day impairments might be higher than initially assumed (<a href="./references#CD010703-bbs2-0112" title="Gunja , N . In the Zzz zone: the effects of Z‐drugs on human performance and driving. Journal of Medical Toxicology2013;9(2):163‐71. ">Gunja 2013</a>). While a first randomised, double‐blind, placebo‐controlled, cross‐over trial did not indicate next‐day residual effects for 3 mg nighttime eszopiclone in young to middle‐aged individuals (<a href="./references#CD010703-bbs2-0016" title="BoyleJ , TrickL , JohnsenS , RoachJ , RubensR . Next‐day cognition, psychomotor function, and driving‐related skills following nighttime administration of eszopiclone. Human Psychopharmacology2008;23(5):385‐97. ">Boyle 2008</a>), a subsequent study applying a mild sleep restriction protocol (<a href="./references#CD010703-bbs2-0017" title="BoyleJ , GroegerJA , PaskaW , CooperJA , RockettC , JonesS , et al. A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. Journal of Clinical Psychopharmacology2012;32(5):704‐9. ">Boyle 2012</a>) demonstrated next‐day impairments, giving reason for a FDA safety alert (see also <a href="#CD010703-sec-0032">Description of the intervention</a>; <a href="./references#CD010703-bbs2-0105" title="Food , DrugAdministration . Eszopiclone containing sleep aids: drug safety communication ‐ can cause next‐day impairment. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm397536.htm (accessed 12 March 2015). ">Food and Drug Administration 2015</a>). Retrospective analyses of medical care and health insurance data demonstrate an alerting risk for falls, injuries, and hip fractures for zolpidem (<a href="./references#CD010703-bbs2-0103" title="FinkleWD , DerJS , GreenlandS , AdamsJL , RidgewayG , BlaschkeT , et al. Risk of fractures requiring hospitalisation after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. Journal of the American Geriatrics Society2011;59(10):1883‐90. ">Finkle 2011</a>; <a href="./references#CD010703-bbs2-0217" title="WangPS , BohnRL , GlynnRJ , MogunH , AvornJ . Zolpidem use and hip fractures in older people. Journal of the American Geriatrics Society2001;49.(12):1685‐90. ">Wang 2001</a>) and for non‐benzodiazepine hypnotic substances in general (<a href="./references#CD010703-bbs2-0067" title="BerrySD , LeeY , CaiS , DoreDD . Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Internal Medicine2013;173(9):754‐61. ">Berry 2013</a>; <a href="./references#CD010703-bbs2-0083" title="DiemSJ , EwingSK , StoneKL , Ancoli‐IsraelS , RedlineS , EnsrudKE , the Osteoporotic Fractures in Men (MrOS) Study Group. Use of non‐benzodiazepine sedative hypnotics and risk of falls in older men. Journal of Gerontology &amp; Geriatric Research2014;3(3):158. ">Diem 2014</a>). Eszopiclone might also decrease immune function, as indicated by a meta‐analysis of data submitted to the FDA, which showed an increased risk of infections for eszopiclone (<a href="./references#CD010703-bbs2-0132" title="JoyaFL , KripkeDF , LovingRT , DawsonA , KlineLE . Meta‐analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. Journal of Clinical Sleep Medicine2009;5(4):377‐83. ">Joya 2009</a>). Carcinogenicity and mutagenesis associated with eszopiclone have been discussed and require further monitoring (<a href="./references#CD010703-bbs2-0209" title="StebbingJ , WatersL , DaviesL , MandaliaS , NelsonM , GazzardB , et al. Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study. Journal of Clinical Oncology2005;23(31):8134‐6. ">Strebbing 2005</a>). </p> <p>It is the aim of the review to integrate efficacy and safety data from randomised controlled trials (RCTs) on eszopiclone, to allow the drawing of conclusions on the drug`s efficacy and safety profile, while taking study quality and bias risks into consideration. This review forms part of a suite of four reviews on non‐benzodiazepine hypnotics for insomnia; the other three reviews will assess the effectiveness and safety of zolpidem (<a href="./references#CD010703-bbs2-0191" title="RösnerS , SoykaM , HajakG , WehrleR . Zolpidem for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010700] ">Rösner 2013a</a>), zopiclone (<a href="./references#CD010703-bbs2-0192" title="RösnerS , SoykaM , HajakG , WehrleR . Zopiclone for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010701] ">Rösner 2013b</a>) and zaleplon (<a href="./references#CD010703-bbs2-0193" title="RösnerS , SoykaM , HajakG , WehrleR . Zaleplon for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010702] ">Rösner 2013c</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010703-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010703-sec-0035"></div> <p>The objectives of the review are:</p> <p> <ol id="CD010703-list-0001"> <li> <p>to determine the effectiveness of eszopiclone for insomnia treatment in comparison with placebo and active comparators; </p> </li> <li> <p>to determine the safety profile of eszopiclone in comparison with placebo and active comparators; and </p> </li> <li> <p>to compare eszopiclone with other non‐benzodiazepine hypnotics in terms of effectiveness and safety. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010703-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010703-sec-0036"></div> <section id="CD010703-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010703-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included parallel group randomised controlled trials (RCTs), comparing eszopiclone with either placebo or active control in its efficacy to improve sleep and its risk of causing adverse events, withdrawal symptoms, or rebound insomnia. Run‐out phases were included if controlled with placebo. Cross‐over trials were not included in the review due to sleep stabilising effects that have been reported for eszopiclone after discontinuation of dosing (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), making it difficult to control carry‐over effects by wash‐out. </p> </section> <section id="CD010703-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults aged 18 years and over with insomnia, as diagnosed using a standardised diagnostic system such as the DSM (<a href="./references#CD010703-bbs2-0058" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM‐5. 5th Edition. Washington DC: American Psychiatric Publishing, 2013. ">American Psychiatric Association 2013</a>), the ICD (<a href="./references#CD010703-bbs2-0223" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: The World Health Organization, 1992. ">World Health Organization 1992</a>), or the ICSD (<a href="./references#CD010703-bbs2-0057" title="American Academy of SleepMedicine . International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD‐3. 3nd. Chicago: American Academy of Sleep Medicine, 2014. ">American Academy of Sleep Medicine 2014</a>), were included irrespective of insomnia type (primary insomnia; insomnia associated with comorbid conditions; see <a href="#CD010703-sec-0142">Differences between protocol and review</a>). We did not include healthy subjects from laboratory models of transient sleep as it is unclear whether these conditions are generalisable to clinical insomnia. </p> </section> <section id="CD010703-sec-0040"> <h4 class="title">Types of interventions</h4> <p><b>Experimental intervention:</b> eszopiclone as monotherapy. </p> <p><b>Comparator interventions:</b> placebo, other non‐benzodiazepine hypnotics, short‐/ intermediate‐/long‐acting benzodiazepines; other active controls that allowed double‐blind treatment. Any treatment setting (inpatient and outpatient) and any formulation were included. </p> </section> <section id="CD010703-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes of the review are a selection of outcomes considered in primary studies (see <a href="./references#CD010703-sec-0144" title="">Characteristics of included studies</a>). We selected the primary and secondary outcomes of the review with regard to the clinical relevance of outcome criteria and the avoidance of conceptual overlaps. All types of measurement including objective measures (e.g. polysomnography) and participant‐reported sleep measures, as well as different types of scores (change from baseline scores, double‐blind average scores), were considered. If both objective and subjective measures were provided in a study publication, subjective measures were included in the meta‐analysis and we examined the impact of measurement type with sensitivity analyses (see <a href="#CD010703-sec-0062">Sensitivity analysis</a>). Change from baseline scores and double‐blind average scores were integrated in the same meta‐analyses, as outlined by <a href="./references#CD010703-bbs2-0080" title="DeeksJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>. For the assessment of adverse events (withdrawal symptoms and next‐day alertness), any types of outcome measures were included. </p> <section id="CD010703-sec-0042"> <h5 class="title">Timing of outcome assessment</h5> <p>Double‐blind average scores were based on the average of the results over the double‐blind treatment period. While change from baseline scores for efficacy outcomes were obtained by subtracting the measurement at the end of treatment from initial scores, change from baseline values for discontinuation outcomes (rebound insomnia) were calculated by subtracting the mean average of the first three nights of the placebo run‐out period from initial scores. Safety was assessed over the entire double‐blind treatment period, and discontinuation effects over the first three nights of the placebo run‐out period. Interventions up to four weeks were considered as short‐term treatments, interventions between four weeks and six months as medium‐term treatments, and interventions with a duration over six months as long‐term treatments. </p> </section> <section id="CD010703-sec-0043"> <h5 class="title">Primary outcomes</h5> <section id="CD010703-sec-0044"> <h6 class="title">Primary efficacy outcomes</h6> <p> <ol id="CD010703-list-0002"> <li> <p>Sleep onset latency (SOL)</p> </li> <li> <p>Wake time after sleep onset (WASO)</p> </li> </ol> </p> <p>Treatment effectiveness was assessed through two outcomes: 1. 'sleep onset latency' (SOL), defined as the length of time (in minutes) after lights‐out until sleep onset, and 2. 'wake time after sleep onset' (WASO), defined as the length of time (in minutes) of wakefulness after the onset of persistent sleep. The consideration of two effectiveness outcomes was reasoned by their conceptual distinctiveness, with SOL measuring a drug's impact on sleep onset, and WASO measuring the potential to improve sleep maintenance; the former reflecting its suitability for the treatment of sleep‐onset insomnia and the latter for sleep‐maintenance insomnia (see <a href="#CD010703-sec-0031">Description of the condition</a>). </p> </section> <section id="CD010703-sec-0045"> <h6 class="title">Primary discontinuation outcomes</h6> <p> <ol id="CD010703-list-0003"> <li> <p>Withdrawal symptoms</p> </li> <li> <p>Rebound insomnia</p> </li> </ol> </p> <p>Discontinuation effects were assessed through 1. withdrawal symptoms, defined as adverse symptoms that either a) appeared for the first time during the placebo run‐out period, or b) already appeared during treatment, but deteriorated during the placebo run‐out interval; and 2.rebound insomnia, defined as the temporary worsening of sleep during the placebo run‐out interval. Worsening of sleep was evaluated as mean change from baseline for the primary efficacy outcomes (SOL, WASO) during the first three days of the placebo run‐out period (<a href="./references#CD010703-bbs2-0109" title="GillinJC , SpinweberCL , JohnsonLC . Rebound insomnia: a critical review. Journal of Clinical Psychopharmacology1989;9(3):161‐72. ">Gillin 1989</a>). The consideration of two variables for assessing effects of drug discontinuation was based on the fact that most studies provided data on either one or the other outcome. </p> </section> </section> <section id="CD010703-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010703-list-0004"> <li> <p>Total sleep time (TST)</p> </li> <li> <p>Next‐day alertness</p> </li> <li> <p>Adverse events (AEs)</p> </li> </ol> </p> <p>Total sleep time (TST) was the total time (in minutes) a person spent sleeping during the in‐bed interval. Calculated as time in bed minus SOL and minus WASO (<a href="./references#CD010703-bbs2-0200" title="Schutte‐RodinS , BrochL , BuysseD , DorseyC , SateiaM . Clinical guideline for the evaluation and management of chronic insomnia in adults. Journal of Clinical Sleep Medicine2008;4(5):487‐504. ">Schutte‐Rodin 2008</a>),TST is a common outcome measure in insomnia treatment, reflecting both sleep onset and maintenance effects within a single variable (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>). To avoid conceptual overlaps with the primary efficacy outcomes, TST was considered as a secondary outcome of the review. Next‐day alertness reflected the state of vigilance the day after hypnotics had been taken and was mainly assessed with an 11‐point‐Likert scale (0 to 10), with higher scores indicating improved function. Adverse events (AEs) were all types of unfavourable symptoms that occurred during the course of the study. </p> <section id="CD010703-sec-0047"> <h6 class="title">Hierarchy of outcome assessment</h6> <p>The study endpoints of the primary outcomes were considered as essential to determine efficacy and safety of eszopiclone, while secondary outcomes had only complementary value in the interpretation of results. Thereby, the primary efficacy outcomes, SOL and WASO, were considered as distinctive compounds and weighted equally in the determination of sleep efficacy. Discontinuation effects were considered as being present if either adverse events or indicators of sleep efficacy changed during the placebo run‐out period. </p> </section> </section> </section> </section> <section id="CD010703-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010703-sec-0049"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Common Mental Disorders Group's Trials Search Co‐ordinator (TSC) searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950 onwards), Embase (1980 onwards), PsycINFO (1987 onwards) and PSYNDEX (in English and German) with a last update of the search on February 10, 2016 (<a href="http://archie.cochrane.org/sections/documents/view?version=16007035346135239146101116112455%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>). The <a href="http://www.who.int/ictrp/" target="_blank">WHO trials portal</a> and <a href="http://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> were searched to identify any ongoing or completed trials with unpublished results. Search strategies were developed by the TSC comprehensively to simultaneously address different non‐benzodiazepine hypnotic compounds (eszopiclone, zopiclone, zolpidem, zaleplon). The results of the search and reviews for zopiclone, zolpidem and zaleplon will be presented in <a href="./references#CD010703-bbs2-0191" title="RösnerS , SoykaM , HajakG , WehrleR . Zolpidem for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010700] ">Rösner 2013a</a>, <a href="./references#CD010703-bbs2-0192" title="RösnerS , SoykaM , HajakG , WehrleR . Zopiclone for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010701] ">Rösner 2013b</a> and <a href="./references#CD010703-bbs2-0193" title="RösnerS , SoykaM , HajakG , WehrleR . Zaleplon for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010702] ">Rösner 2013c</a>, respectively. </p> <p>In keeping with the MECIR conduct standard (C37 re‐running searches within 12 months of publication), we ran an update search on CENTRAL, CCMDCTR, MEDLINE, Embase, PsycINFO and the international trial registries (21 February 2018). We identified three new studies which we have placed in 'awaiting classification'/'ongoing studies', these will be incorporated in the next version of the review, as appropriate. </p> </section> <section id="CD010703-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We contacted key informants, experts, public sponsors, and drug manufacturers with the request to indicate further studies of potential relevance. For this purpose, we provided reference lists with identified studies and the criteria for inclusion and exclusion in the review. Finally, we handsearched the reference lists of included studies and current reviews to complete and to verify the preceding searches. All eligible studies identified with the search were included irrespective of language, publication type, or status. </p> </section> </section> <section id="CD010703-sec-0051"> <h3 class="title" id="CD010703-sec-0051">Data collection and analysis</h3> <section id="CD010703-sec-0052"> <h4 class="title">Selection of studies</h4> <p>We assessed the eligibility and relevance of trials on the basis of their abstracts retrieved from the electronic searches. For studies that appeared to meet the inclusion criteria according to the abstract information, we obtained full‐text versions for closer inspection. Two review authors assessed the relevance and eligibility of studies independently. The process of study identification and its results were outlined as a flow diagram according to the PRISMA statement (<a href="./references#CD010703-bbs2-0160" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. ">Moher 2009</a>). </p> </section> <section id="CD010703-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>Two review authors extracted relevant outcome data independently into prespecified data extraction forms and compared data value by value. In case of disagreements, we have undertaken the following sequential procedures in descending order: </p> <p> <ol id="CD010703-list-0005"> <li> <p>comparison of published and extracted information to identify transcription and comprehension errors; </p> </li> <li> <p>explanation of the coding decisions by each review author, followed by consensus discussion and arbitration. </p> </li> </ol> </p> <p>Finally, after comparisons and corrections were concluded, we entered data into the Review Manager software (<a href="./references#CD010703-bbs2-0178" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). For meta‐analyses, we planned to compare eszopiclone individually with either placebo or active control (though we only found placebo‐controlled trials). It had been planned to group benzodiazapine‐active control drugs according to their duration of action into short‐acting (less than five hours), intermediate‐acting (five to 24 hours) and long‐acting (more than 24 hours) agents (<a href="./references#CD010703-bbs2-0110" title="GreenblattDJ , ShaderRI , DivollM , HarmatzJS . Benzodiazepines. A summary of pharmacokinetic properties. British Journal of Clinical Pharmacology1981;11(Suppl 1):11‐6. ">Greenblatt 1981</a>), potentially generating the following comparisons: </p> <p> <ol id="CD010703-list-0006"> <li> <p>eszopiclone versus placebo:</p> </li> <li> <p>eszopiclone versus other new generation hypnotics;</p> </li> <li> <p>eszopiclone versus short‐acting benzodiazepines;</p> </li> <li> <p>eszopiclone versus intermediate‐acting benzodiazepines;</p> </li> <li> <p>eszopiclone versus long‐acting benzodiazepines;</p> </li> <li> <p>eszopiclone versus other active controls (compounds to be specified at a later date).</p> </li> </ol> </p> </section> <section id="CD010703-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in accordance with The Cochrane Collaboration's 'Risk of bias' assessment tool (<a href="./references#CD010703-bbs2-0123" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester (UK), 2011:243‐96. ">Higgins 2011</a>). We considered the equivalence of baseline characteristics and the equivalence of treatment utilisation as further bias risks in the rating of the item 'free of other bias'. We judged the general susceptibility to bias effects in consideration of the objectivity of outcome information and rated this separately for measures of sleep and next‐day functioning. Two review authors independently assessed the risk of bias and divergent ratings were resolved by consensus discussion. The criteria considered as constitutive for the rating of bias risks are outlined in <a href="./appendices#CD010703-sec-0134">Appendix 1</a>. </p> </section> <section id="CD010703-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>We measured treatment effects for continuous outcomes with the mean differences (MD), as these were measured on the same scale. As more commonly reported, we gave priority to final measurement scores compared to change‐from‐baseline scores, if both types of outcomes were provided in the trial publication. Nevertheless, we pooled change and final scores in meta‐analysis as outlined by <a href="./references#CD010703-bbs2-0080" title="DeeksJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>, using the (unstandardized) mean difference method in RevMan (<a href="./references#CD010703-bbs2-0178" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). For subjective measures of next‐day functioning, higher scores indicate a more positive state; if provided differently in the primary study, scales were reversed in their polarity. Adverse events were assessed using risk difference (RD) as this measure can also be calculated in cases where there are no events in either group (<a href="./references#CD010703-bbs2-0080" title="DeeksJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We calculated all treatment effects together with 95% confidence intervals (CIs). A P value of 0.05 and below has been chosen to indicate statistical significance of effects. We planned to measure treatment effects for dichotomous effectiveness outcomes using risk ratio (RR) and ‘number needed to treat for an additional beneficial outcome’ (NNTB) or ‘number needed to treat for an additional harmful outcome’ (NNTH) for outcomes that reached statistical significance, but, beside adverse events, no additional dichotomous data were available. We did not provide NNTH for adverse events as these related to the number of events, not participants (see <a href="#CD010703-sec-0056">Unit of analysis issues</a>). In the future, if we find any dichotomous data, we plan to calculate NNTB for effects on binary outcomes which reach statistical significance. </p> </section> <section id="CD010703-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>Only individually randomised trials with the individual participant constituting the unit of analysis were included in the review. In multi‐arm studies with different dose schedules, only the initially recommended dose group (2 mg in non‐elderly, 1 mg in elderly participants; see <a href="#CD010703-sec-0040">Types of interventions</a>) was considered. Meta‐analyses of adverse events were based on number of events, which did not necessarily correspond with the number of participants (as one participant can theoretically report multiple adverse events). The latter did not apply to dropouts due to adverse events, where the number of participants matched exactly the number of dropout events. </p> </section> <section id="CD010703-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>Outcome statistics were included in the review, as provided by the study publications, irrespective of how missing individuals were handled in the primary analysis. We imputed sample sizes for continuous outcomes which were not explicitly provided in the trial publication by the size of treatment‐received samples or, if not available, by the size of the randomised sample. Missing standard deviations were obtained from standard errors (SEs) or CIs for group means, missing SEs from standard deviations (SDs), CIs, or t values and P values. If only the medians were provided in the trial publications, outcome statistics were not included in the meta‐analyses, but information on the significance of effects (yes, no) was inserted into an overview table and described qualitatively in the discussion of results. </p> </section> <section id="CD010703-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified inconsistency across studies with the I<sup>2</sup> statistic (<a href="./references#CD010703-bbs2-0122" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>), using threshold values for substantial heterogeneity as outlined by <a href="./references#CD010703-bbs2-0080" title="DeeksJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>. Heterogeneity was assumed if the I<sup>2</sup> value was above 75%. The Tau<sup>2</sup> statistic was additionally considered to provide an estimate of between‐study variance (<a href="./references#CD010703-bbs2-0194" title="RückerG , SchwarzerG , CarpenterJR , SchumacherM . Undue reliance on I2 in assessing heterogeneity may mislead. BMC Medical Research Methodology2008;8:79. ">Rücker 2008</a>), independent of the sample size. In cases of heterogeneity, we attempted to identify and explain the heterogeneity using subgroup analysis. </p> </section> <section id="CD010703-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>If there are more than 10 included studies in future versions of this review, we will graphically illustrate the risk of publication bias with the funnel plot method (<a href="./references#CD010703-bbs2-0091" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. British Medical Journal1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD010703-bbs2-0146" title="LightRJ , PillemerBD . The Science of Reviewing Research. Cambridge (MA): Harvard University Press, 1984. ">Light 1984</a>). </p> </section> <section id="CD010703-sec-0060"> <h4 class="title">Data synthesis</h4> <p>For synthesising aggregate outcome measures, we used a random‐effects model (<a href="./references#CD010703-bbs2-0082" title="DerSimonianR , LairdNM . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>), with study effects being weighted using the Mantel‐Haenszel approach (<a href="./references#CD010703-bbs2-0150" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective disease. Journal of the National Cancer Institute1959;22:719–48. ">Mantel 1959</a>). </p> </section> <section id="CD010703-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to age‐related changes in the architecture of sleep and pharmacokinetic changes, elderly participants are repeatedly shown to respond differently to hypnotic drugs than younger people (<a href="./references#CD010703-bbs2-0084" title="DolderC , NelsonM , McKinseyJ . Use of non‐benzodiazepine hypnotics in the elderly: are all agents the same?. CNS Drugs2007;21(5):389‐405. ">Dolder 2007</a>). In addition, there is evidence that treatment effects might depend on insomnia as a primary or secondary condition (<a href="./references#CD010703-bbs2-0138" title="KrystalAD , McCallWV , FavaM , JoffeH , SoaresCN , HuangH , et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. The Primary Care Companion for CNS Disorders2012;14(4):doi: 10.4088/PCC.11m01296. [DOI: 10.4088/PCC.11m01296] ">Krystal 2012b</a>; <a href="./references#CD010703-bbs2-0220" title="WilsonSJ , NuttDJ , AlfordC , ArgyropoulosSV , BaldwinDS , BatesonAN , et al. British Association for Psychopharmacology consensus statement on evidence‐based treatment of insomnia, parasomnias and circadian rhythm disorder. Journal of Psychopharmacology2010;24(11):1577‐601. ">Wilson 2010</a>). Thus, we conducted subgroup analyses limited to samples, a) of age groups over 65 years and b) of participants with insomnia associated with psychiatric and medical comorbidity to determine differential effectiveness of eszopiclone in participants with older age or with comorbid insomnia. To additionally investigate whether effects demonstrated in investigator‐initiated studies significantly differed from sponsor‐initiated studies as a result of funding bias (<a href="./references#CD010703-bbs2-0143" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Brisitsh Medical Journal2003;31(326):1167‐70. ">Lexchin 2003</a>), we compared both groups of trials by subgroup analyses. </p> </section> <section id="CD010703-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to determine the influence of the following variables on the primary effectiveness outcomes (SOL, WASO): </p> <p> <ol id="CD010703-list-0007"> <li> <p>the method of sleep efficacy measurement by integrating effects measured with polysomnography;</p> </li> <li> <p>the method of withdrawal assessment by integrating scores of the Benzodiazepine Withdrawal Symptom Questionnaire. </p> </li> </ol> </p> <section id="CD010703-sec-0063"> <h5 class="title">Summary of findings tables</h5> <p>Summary of findings tables were completed to summarise the best evidence for all relevant outcomes including SOL, WASO, withdrawal symptoms, rebound insomnia, TST, next‐day alertness and adverse events. The rating of single GRADE criteria for downgrading (risk of bias, inconsistency, indirectness, imprecision, publication bias) and upgrading quality of evidence (magnitude, dose‐response gradient, change of results by confounding) was reasoned and outlined in detail under <a href="#CD010703-sec-0119">Quality of the evidence</a>. The GRADE assessment was performed by one author (SRO) and discussed with a second author (CE) in case of ambiguity. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010703-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010703-sec-0064"></div> <section id="CD010703-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD010703-sec-0066"> <h4 class="title">Results of the search</h4> <section id="CD010703-sec-0067"> <h5 class="title">Search for studies</h5> <p>Results of the electronic biomedical database searches (to February 2016), simultaneously addressing different non‐benzodiazepine hypnotic compounds (eszopiclone, zopiclone, zolpidem, zaleplon) were screened in parallel (by SR, CE) and allocated to different reviews, as appropriate. Results of the search and reviews for zopiclone, zolpidem and zaleplon will be presented in <a href="./references#CD010703-bbs2-0191" title="RösnerS , SoykaM , HajakG , WehrleR . Zolpidem for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010700] ">Rösner 2013a</a>, <a href="./references#CD010703-bbs2-0192" title="RösnerS , SoykaM , HajakG , WehrleR . Zopiclone for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010701] ">Rösner 2013b</a> and <a href="./references#CD010703-bbs2-0193" title="RösnerS , SoykaM , HajakG , WehrleR . Zaleplon for insomnia. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD010702] ">Rösner 2013c</a>, respectively. The steps of trial identification for eszopiclone and their results are illustrated in <a href="#CD010703-fig-0001">Figure 1</a> as a flow diagram, according to the PRISMA statement (<a href="./references#CD010703-bbs2-0160" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. ">Moher 2009</a>). </p> <div class="figure" id="CD010703-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (search results to Feb 2016)" data-id="CD010703-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (search results to Feb 2016)</p> </div> </div> </div> <p>Electronic searches for eszopiclone (only) yielded 222 potentially relevant journal references. Personal communications with investigators and sponsors did not yield further studies. From the 222 yielded references, 94 were recognised as duplicates and removed. For the remaining 128 references, abstracts were screened by two review authors independently (SR, CE and RW, CE). On the basis of information provided in the title and abstracts, a further 80 references were excluded, while for the remaining 48 records, full‐text articles were retrieved (where available). Inspection of the study reports led to the exclusion of a further 33 studies (34 reports) and reasons for the exclusions are outlined under <a href="#CD010703-sec-0083">Excluded studies</a>. </p> <p>The search of the international trial registries (to February 2016) identified an additional 44 trial protocols; 15 were excluded as irrelevant and, on closer inspection, 15 were duplicates as they had already been excluded as trial records retrieved from the bibliographic databases search, with the reasons for exclusions outlined under Excluded studies. Of the remaining 14 trial protocols, eight linked to full study reports already included in the review, four were added to 'awaiting classification', one was ongoing and there was one duplicate trial registration. </p> <p>In keeping with the MECIR conduct standard (c37: re‐running searches within 12 months of publication), we ran an update search (21 February 2018) and identified four new studies, two studies (<a href="./references#CD010703-bbs2-0049" title="BaranB , DemanueleC , VuperTC . The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a double‐blind randomised trial. Sleep Conference: 31st Anniversary Meeting of the Associated Professional Sleep Societies, LLC, SLEEP. United States, 2017; Vol. 40:A415. ">Baran 2017</a>; <a href="./references#CD010703-bbs2-0050" title="BuxtonOM , PavlovaMK , O'ConnorSP , WangW , WinkelmanJW . Lack of change in glucose metabolism in eszopiclone‐treated primary insomnia patients. Nature and Science of Sleep2017;9:187‐98. ">Buxton 2017</a>) placed in 'studies awaiting classification', one (<a href="./references#CD010703-bbs2-0056" title="NCT02456532 . Safety and efficacy of chronic hypnotic use 2 (CIS2). clinicaltrials.gov/ct2/show/NCT02456532 (first received 28 May 2015). ">NCT02456532</a>) placed in ongoing studies and another (retrospectively) excluded (<a href="./references#CD010703-bbs2-0048" title="UchimuraN , KamijoA , KuwaharaH , UchiyamaM , ShimizuT , ChibaS , InoueY . A randomized placebo‐controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Med2012;13(10):1247‐53. ">Uchimura 2012b</a>). Thus, including the results of the update search, six studies were categorized as 'studies awaiting classification',two studies as ongoing and a total of 34 excluded studies. A journal article relating to a trial protocol awaiting classification (NCT01100164) was also identified at this time (<a href="./references#CD010703-bbs2-0054" title="NCT01100164 . A Non‐inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg ‐ for the Treatment of Insomnia (Eszo). https://clinicaltrials.gov/ct2/show/NCT011001642010. PintoLRJr , BittencourtLR , TreptowEC , BragaLR , TufikS . Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (Sao Paulo)2016; Vol. 71, issue 1:5‐9. ">Pinto 2016</a>). </p> <p>Finally, 14 RCTs were eligible for the review; of these, 13 RCTs provided data for meta‐analytic integrations of sleep efficacy or safety outcomes. </p> <p>The PRISMA diagram includes details of the search results to 10 February 2016 only (<a href="#CD010703-fig-0001">Figure 1</a>). </p> </section> <section id="CD010703-sec-0068"> <h5 class="title">Acquisition of unreported outcomes</h5> <p>To obtain unreported outcome data for primary efficacy outcomes of the review, correspondence authors of primary studies were contacted by email and requested to provide unreported data. From 10 authors requested, six authors responded, referring to the drug manufacturer, Sunovion (www.sunovion.com/), which did not provide unreported data. </p> </section> </section> <section id="CD010703-sec-0069"> <h4 class="title">Included studies</h4> <p>Fourteen RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), based on data from 4732 study participants, were included in the review. <a href="#CD010703-tbl-0002">Table 1</a> provides an overview of all included studies. Detailed information on study designs, sample characteristics, interventions, and outcomes for each individual trial is presented in the <a href="./references#CD010703-sec-0144" title="">Characteristics of included studies</a> tables. </p> <div class="table" id="CD010703-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific sample characteristics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration (weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single‐blind run‐out (days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>— (follow‐up)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS), PSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary); actigraphy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>— (follow‐up)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid Parkinsons disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid anxiety disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid rheumatoid arthritis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (open label)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS), PSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>IVRS: interactive voice response system</sup> </p> <p><sup>N: number</sup> </p> <p><sup>PSG: polysomnography</sup> </p> </div> </div> <section id="CD010703-sec-0070"> <h5 class="title">Design and setting</h5> <p>All trials included in the review were based on a randomised controlled parallel group design. No trials with active controls (new‐generation hypnotics, short‐acting benzodiazepines, intermediate‐acting benzodiazepines, long‐acting benzodiazepines) were included, limiting comparisons to 'eszopiclone versus placebo'. Eszopiclone and placebo were provided as home treatment; three of the 14 RCTs (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), additionally included overnight stays in the sleep laboratory. All studies but three <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>, <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>, <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a> were based on multicentre designs, including 43 (<a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>), and up to 82 (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>), participating study centres. Thirteen RCTs were undertaken in the United States, and one trial in Canada (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) Follow‐up after drug discontinuation was considered in ten RCTs, of which seven applied single‐blind placebo run‐out periods (2 days <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>, 7 days <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> and 14 days <a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>), two open‐label extensions (2 weeks <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>, 6 months <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>), and one trial with naturalistic follow‐up monthly by telephone for four months after randomised treatment (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>). There was a single‐blind placebo run‐in period to establish baseline values for sleep and daytime functioning and to ensure compliance with the dosing regimen preceded treatment in some trials (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). </p> </section> <section id="CD010703-sec-0071"> <h5 class="title">Sponsoring, initiation and publication</h5> <p>With the exception of two non‐profit funded RCTs (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>), trials included in the review were financially supported by the pharmaceutical industry. Five of the 14 included RCTs were initiated by the investigator (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), and the remaining nine RCTs by a sponsor. All trials were published as journal articles. </p> </section> <section id="CD010703-sec-0072"> <h5 class="title">Sample size</h5> <p>Sample sizes varied from 30 (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>) to 830 participants (<a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>), with most studies including between 150 to 400 participants (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). </p> </section> <section id="CD010703-sec-0073"> <h5 class="title">Participants: age</h5> <p>In most RCTs included in the review, participants were recruited from young to middle‐aged groups (18 to 64 years), three RCTs defined older age (64 and 85 years) as a criterion of inclusion (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), while in the trial of <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>, a broader spectrum of age was considered (35 to 85 years). The mean age of participants varied between 40 and 50 years in most studies; in the studies with elderly participants (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), mean age was 71.5 years, and in the trial with the broader age range (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>), mean age of participants was 56 years. </p> </section> <section id="CD010703-sec-0074"> <h5 class="title">Participants: gender</h5> <p>RCTS were based on mixed‐gender samples, apart from one trial testing eszopiclone after menopausal transition (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>), thus exclusively including only female participants. In mixed‐gender samples, females constituted the majority of participants by representing 63% and 67% of the sample. A higher proportion of females was seen in the trials focusing on comorbid rheumatoid arthritis (86.9%; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>) and migraineurs (82.5%; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), and a lower proportion in the trial with comorbid Parkinson's disease (20%; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>). </p> </section> <section id="CD010703-sec-0075"> <h5 class="title">Participants: insomnia diagnosis</h5> <p>Participants of included trials either met DSM‐5 or DSM‐4‐TR criteria for primary insomnia (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), or DSM‐5 criteria for insomnia associated with a comorbid psychiatric or medical condition (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). </p> <p>The study conducted by <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>, including participants with primary insomnia and suffering migraine, took an intermediate position between primary insomnia studies and comorbidity trials. Total sleep time (TST) was required to be lower than six hours in two studies (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>), or 6.5 hours (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), and wake time after sleep onset (WASO) had to be at least 30 minutes (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), or 45 minutes (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). Insomnia symptoms had to occur at least three nights per week (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), on a typical night (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>), or each night during the last month (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). </p> </section> <section id="CD010703-sec-0076"> <h5 class="title">Participants: comorbidity</h5> <p>Comorbid conditions associated with insomnia included major depression (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>), general anxiety disorder (<a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>), chronic low back pain (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), Parkinson's`s disease (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>), rheumatoid arthritis (<a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>), and complaints in the context of the menopausal transition (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). Some trials demanded that comorbid symptoms must either have predated insomnia (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>), or postdated insomnia less than four weeks (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>) or 10 weeks (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>). In the remaining studies considering comorbidity, no temporal relationship between insomnia and comorbid disorders was required (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>). Individuals with another primary or secondary sleep disorder (e.g. sleep apnea, restless legs syndrome, periodic leg movement disorder) or with a known or suspected acute medical or psychiatric condition that impacted or was likely to impact sleep, were excluded. </p> <p>A lifetime history of substance abuse or dependence was a criterion of exclusion in five of 14 RCTs (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), while other studies excluded participants only if substance abuse or dependence occurred within the last 12 months (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), five years (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), or was present at screening (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>). Some trials also defined positive urine screening for drugs or alcohol (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>), drinking more than two standard drinks per day (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) or more than 14 drinks per week (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>) as a criterion of exclusion. Even so, four RCTs (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) did not mention substance use or substance use disorders as a criterion of exclusion. </p> </section> <section id="CD010703-sec-0077"> <h5 class="title">Intervention: comparisons and doses</h5> <p>Twelve of the 14 RCTs used a two‐armed design, testing eszopiclone dosed as recommended (3 mg for non‐elderly, 2 mg for elderly participants) against placebo, and two RCTs (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) compared recommended doses of eszopiclone with lower dose groups (2 mg for non‐elderly in <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>; 1 mg for elderly participants in <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) using a three‐armed design. From these trials, only the initially recommended dose groups (3 mg for non‐elderly, 2 mg for elderly participants) were included in the meta‐analytic integration. For home treatment, participants were instructed to take study medication at bedtime, in the sleep laboratory condition (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), or a single bedtime dose was administered 30 minutes before lights out. </p> </section> <section id="CD010703-sec-0078"> <h5 class="title">Intervention: comedication</h5> <p>Eszopiclone was coadministered with open‐label fluoxetine (starting dose 20 mg; dose range: 20 to 40 mg/day) in participants with coexisting major depressive disorder (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>), open‐label escitalopram (10 mg) in participants with comorbid generalised anxiety disorder (<a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>), naproxen (50 mg open‐label; twice daily) and lansoprazole (15 mg open‐label; once daily) in participants with low back pain (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), open‐label hormones for menopause symptoms (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) or open‐label disease‐modifying medications for Parkinson's`s disease (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>) and rheumatoid arthritis (<a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>). </p> </section> <section id="CD010703-sec-0079"> <h5 class="title">Intervention: treatment duration</h5> <p>Single‐blind placebo run‐in periods were used to establish baseline values for sleep and daytime functioning and to ensure compliance with the dosing regimen in some trials (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). Duration of treatment with eszopiclone and placebo varied from two weeks (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) to 24 weeks (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>), including short‐term treatment of insomnia (≤ four weeks; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>), medium‐term treatment (&gt; four weeks ≤ six months; <a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) and long‐term treatment (&gt; six months; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). Length of follow‐up intervals was two days (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), one week (<a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) or two weeks (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>) for placebo run‐out periods, and four months (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>) or six months (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>) for open‐label or naturalistic follow‐up extensions. </p> </section> <section id="CD010703-sec-0080"> <h5 class="title">Outcomes: sleep efficacy</h5> <p>Sleep efficacy outcomes (SOL, WASO, TST) constituted the primary efficacy endpoints in all but one trial focusing on health‐related quality of life (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>). Besides latency to persistent sleep (LPS), WASO and TST, <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> additionally analysed time and percentage of time spent in the different sleep stages. Sleep efficacy outcomes were either provided as mean change from baseline values (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) or mean values defined as the average over a defined time interval or the entire double‐blind treatment period (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). Due to the skewed distribution of data, for some trials medians were exclusively (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>) or additionally reported (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). The trial focusing on quality of life (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>) reported ß‐, SE and t‐values for repeated measures mixed modelling. Sleep efficacy outcomes were assessed through participant self‐reports in all but three RCTs (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) which included both participant‐reported and objective measures of sleep. Objective sleep measures were assessed via polysomnography (PSG) recording during overnight stays in the sleep laboratory (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) and via actigraphy (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>), where participants continuously wore an actigraph unit on their non‐dominant wrist for the duration of the study. Participant self‐reports on sleep were assessed with paper sleep diaries (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>) or electronic sleep diaries (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>) completed in the morning or with the aid of an interactive voice response system (IVRS; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) that had either to be called daily (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) or weekly (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>) in the morning to report the previous night’s sleep. </p> </section> <section id="CD010703-sec-0081"> <h5 class="title">Outcomes: discontinuation effects</h5> <p>Rebound effects, assessed through change from baseline for sleep efficacy outcomes during placebo run‐out period, were provided for seven RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). One RCT provided means for change from baseline for each single day during placebo run‐out (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>), the remaining trials either reported median change values (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) or referred to the significance of effects without providing outcome statistics (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>). Prevalence of new or worsening of adverse events ( <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) or central nervous system‐related adverse events (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) reflecting withdrawal effects were provided by seven RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). In two trials (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>), withdrawal effects were evaluated with the Benzodiazepine Withdrawal Symptom Questionnaire (<a href="./references#CD010703-bbs2-0212" title="TyrerP , MurphyS , RileyP . The Benzodiazepine Withdrawal Symptom Questionnaire. Journal of Affective Disorders1990;19:53‐61. ">Tyrer 1990</a>) administered following the discontinuation period. </p> </section> <section id="CD010703-sec-0082"> <h5 class="title">Outcomes: next‐day functioning</h5> <p>Daytime functioning was recorded in the evening with electronic wake diaries (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>) or by evening calls to the interactive voice response system (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). Next‐day functioning was rated on an 11‐point Likert scale (0 to 10), with higher scores indicating improved functioning (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>, in one RCT (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), next‐day residual effects were additionally evaluated with the Digit‐Symbol Substitution Test (DSST; <a href="./references#CD010703-bbs2-0219" title="WechslerD . Manual for the Wechsler scale. New York, NY: Psychological Corporation, 1955. ">Wechsler 1955</a>). </p> </section> </section> <section id="CD010703-sec-0083"> <h4 class="title">Excluded studies</h4> <p>Thirty‐four studies were excluded on the basis of full‐text papers. Among reasons for exclusion, insomnia diagnosis not being mandatory for including subjects in the primary study (<a href="./references#CD010703-bbs2-0015" title="AttarianH , ApplebeeG , ApplebeeA , WangB , ClarkM , McCormickB , et al. Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients. International Journal of MS Care2011;13(2):84‐90. ">Attarian 2011</a>; <a href="./references#CD010703-bbs2-0018" title="DemanueleC , BartschU , WamsleyEJ , ShinnAK , GoffDC , JonesMW . The effects of eszopiclone on slow wave modulation of sleep spindles in schizophrenia. 69th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. New York, United States, 2014. ">Demanuele 2014</a>; <a href="./references#CD010703-bbs2-0019" title="DimsdaleJE , BallED , CarrierE , WallaceM , HolmanP , MulroneyC . Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Supportive Care in Cancer2011;19:2015‐20. ">Dimsdale 2011b</a>; <a href="./references#CD010703-bbs2-0020" title="EckertDJ , OwensRL , KehlmannGB , WellmanA , RahangdaleS , Yim‐YehS , et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clinical Science2011;120(12):505‐14. ">Eckert 2011</a>; <a href="./references#CD010703-bbs2-0025" title="LettieriCJ , QuastTN , EliassonAH , AndradaT . Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo‐controlled trial. Sleep2008;31(9):1310‐6. ">Lettieri 2008</a>; <a href="./references#CD010703-bbs2-0029" title="NCT00460993 . Efficacy &amp; safety of eszopiclone (Lunesta) in nursing home patients. clinicaltrials.gov/show/NCT000460993 (first received 17 April 2007). ">NCT00460993</a>; <a href="./references#CD010703-bbs2-0030" title="NCT00511134 . Study of lunesta versus placebo for sleep problems related to smoking cessation and zyban. clinicaltrials.gov/ct2/show/NCT00511134 (first received 3 August 2007). ">NCT00511134</a>; <a href="./references#CD010703-bbs2-0031" title="NCT00616655 . Generalized anxiety disorder proof of concept efficacy and safety study of SEP‐225441 (eszopiclone) In GAD subjects. clinicaltrials.gov/show/NCT000616655 (first received 15 February 2008). ">NCT00616655</a>; <a href="./references#CD010703-bbs2-0032" title="NCT00685269 . Safety and efficacy of eszopiclone with mild to moderate obstructive sleep apnea syndrome (OSAS). clinicaltrials.gov/show/NCT00685269 (first received 28 May 2008). ">NCT00685269</a>; <a href="./references#CD010703-bbs2-0033" title="NCT00811746 . Hypnotics to improve polysomnography yield: eszopiclone vs ramelteon?. clinicaltrials.gov/show/NCT00811746 (first received 19 December 2008). ">NCT00811746</a>; <a href="./references#CD010703-bbs2-0034" title="NCT00813735 . Eszopiclone co‐administered with escitalopram for insomnia in elderly adults with major depressive disorder. clinicaltrials.gov/ct2/results?term=NCT00813735 (first received 23 December 2008). ">NCT00813735</a>; <a href="./references#CD010703-bbs2-0035" title="NCT00826111 . The effects of eszopiclone and lexapro on prefrontal glutamate and GABA in depression with anxiety and insomnia. clinicaltrials.gov/show/NCT00826111 (first received 21 January 2009). ">NCT00826111</a>; <a href="./references#CD010703-bbs2-0038" title="NCT011022270 . The effect of eszopiclone on the arousal threshold in sleep apnea syndrome. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010‐ [cited 2015 April 15]. Available from: clinicaltrials.gov/show/NCT01102270 NLM Identifier: NCT01102270 (first received 13 April 2010). ">NCT01102270</a>; <a href="./references#CD010703-bbs2-0039" title="NCT01641900 . Effects of eszopiclone on sleep and memory in schizophrenia. clinicaltrials.gov/show/NCT01641900 (first received 17 July 2012). ">NCT01641900</a>; <a href="./references#CD010703-bbs2-0046" title="TekC , PalmeseLB , KrystalAD , DeGeorgePC , ReutenauerEL , GuloksuzS . The impact of eszopiclone insomnia treatment on cognition in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. 69th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. New York, United States, 2014. ">Tek 2014</a>, <a href="./references#CD010703-bbs2-0023" title="HuangY , ZhengY . Sleep disorder of schizophrenia treated with shallow needling: a randomised controlled trial. Zhongguo Zhenjiu2015;35(9):869‐73. ">Huang 2015</a>) was most common (n = 16). Further reasons for exclusion were the use of a cross‐over design (<a href="./references#CD010703-bbs2-0016" title="BoyleJ , TrickL , JohnsenS , RoachJ , RubensR . Next‐day cognition, psychomotor function, and driving‐related skills following nighttime administration of eszopiclone. Human Psychopharmacology2008;23(5):385‐97. ">Boyle 2008</a>; <a href="./references#CD010703-bbs2-0017" title="BoyleJ , GroegerJA , PaskaW , CooperJA , RockettC , JonesS , et al. A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. Journal of Clinical Psychopharmacology2012;32(5):704‐9. ">Boyle 2012</a>; <a href="./references#CD010703-bbs2-0021" title="ErmanMK , ZammitG , RubensR , SchaeferK , WesselT , AmatoD , et al. A polysomnographic placebo‐controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. Journal of Clinical Sleep Medicine2008;4(3):229‐34. ">Erman 2008</a>; <a href="./references#CD010703-bbs2-0026" title="NCT00120250 . Eszopiclone for sleep disturbance and nightmares in post‐traumatic stress disorder. clinicaltrials.gov/show/NCT000120250 (first received 15 July 2005). ">NCT00120250</a>; <a href="./references#CD010703-bbs2-0027" title="NCT00368056 . Effects of one evening dose of 3 mg eszopiclone on next day driving ability. clinicaltrials.gov/ct2/results?term=NCT00368056 (first received 24 August 2006). ">NCT00368056</a>; <a href="./references#CD010703-bbs2-0028" title="NCT00374192 . The treatment of insomnia in symptomatic peri‐ and postmenopausal women. clinicaltrials.gov/ct2/show/NCT00374192 (first received 11 September 2006). ">NCT00374192</a>; <a href="./references#CD010703-bbs2-0037" title="NCT00900159 . Effects of daytime eszopiclone administration in shift workers. clinicaltrials.gov/show/NCT00900159 (first received 12 May 2009). ">NCT00900159</a>; <a href="./references#CD010703-bbs2-0042" title="PollackMH , HogeEA , WorthingtonJJ , MoshierSJ , WechslerRS , BrandesM , et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomised, double‐blind, placebo‐controlled trial. Journal of Clinical Psychiatry2011;72(7):892‐7. ">Pollack 2011</a>; <a href="./references#CD010703-bbs2-0044" title="RosenbergR , RoachJM , ScharfM , AmatoDA . A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Medicine2007;8(5):464‐70. ">Rosenberg 2007</a>; <a href="./references#CD010703-bbs2-0047" title="InoueY , KamijoA , NagaiR . Patient background factors affecting the therapeutic outcomes in response to eszopiclone in adult patients with chronic insomnia: A post hoc analysis of a double‐blind phase III study in Japan. Journal of Clinical Sleep Medicine2015;15(11):1171‐8. UchimuraN , KamijoA , TakaseT . Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and non‐elderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24‐week, randomised, double‐blind study. Annals of General Psychiatry2012;25(11):2‐15. ">Uchimura 2012a</a>; <a href="./references#CD010703-bbs2-0048" title="UchimuraN , KamijoA , KuwaharaH , UchiyamaM , ShimizuT , ChibaS , InoueY . A randomized placebo‐controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Med2012;13(10):1247‐53. ">Uchimura 2012b</a>), an open‐label design (<a href="./references#CD010703-bbs2-0022" title="GrossCR , KreitzerMJ , Reilly‐SpongM , WallM , WinbushNY , PattersonR , et al. Mindfulness‐based stress reduction versus pharmacotherapy for chronic primary insomnia: a randomized controlled clinical trial. Explore2011;7(2):76‐87. ">Gross 2011</a>; <a href="./references#CD010703-bbs2-0036" title="NCT00889200 . Eszopiclone treatment &amp; cortisol responsitivity. clinicaltrials.gov/show/NCT00889200 (first received 28 April 2009). ">NCT00889200</a>; <a href="./references#CD010703-bbs2-0037" title="NCT00900159 . Effects of daytime eszopiclone administration in shift workers. clinicaltrials.gov/show/NCT00900159 (first received 12 May 2009). ">NCT00900159</a>; <a href="./references#CD010703-bbs2-0040" title="NCT01710631 . Twelve month study of the safety of eszopiclone in adult subjects with insomnia. clinicaltrials.gov/show/NCT01710631 (first received 19 October 2012). ">NCT01710631</a>; <a href="./references#CD010703-bbs2-0041" title="PengY . Efficacy of eszopiclone combined with psychotherapy in the treatment of insomnia. Chinese Journal of New Drugs2013;22:443‐6. ">Peng 2013</a>), the inclusion of healthy subjects passing through a model of transient insomnia (<a href="./references#CD010703-bbs2-0043" title="RosenbergR , CaronJ , RothT , AmatoD . An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Medicine2005;6(1):15‐22. ">Rosenberg 2005</a>) and younger age participants (&lt; 18 years) (<a href="./references#CD010703-bbs2-0045" title="SangalRB , BlumerJL , LankfordDA , GrinnellTA , HuangH . Eszopiclone for insomnia associated with attention‐deficit/hyperactivity disorder. Pediatrics2014;134(4):1095‐103. ">Sangal 2014</a>). Individual trials excluded from the review and the corresponding reasons for exclusion are outlined under <a href="./references#CD010703-sec-0145" title="">Characteristics of excluded studies</a>. </p> <section id="CD010703-sec-0084"> <h5 class="title">Ongoing studies</h5> <p>Searches in registry databases (<a href="http://www.who.int/ictrp/" target="_blank">WHO trials portal</a>; <a href="http://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>) (to February 2016) yielded one trial (<a href="./references#CD010703-bbs2-0055" title="EmikoH , TsuyoshiM . Efficacy and safety of eszopiclone in the treatment of insomnia complicated with nocturnal awakenings associated with urination. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000015966&amp;language=E (accessed 16‐Feb‐2016). ">Emiko 2015</a>) in the stage of 'currently recruiting', which seemed to meet the inclusion criteria of the review. In this randomised study, conducted at the School of Medicine at Nihon University, efficacy and safety of eszopiclone was examined for the treatment of insomnia complicated with nocturnal awakenings. The other ongoing study, under consideration after the update search in February 2018, was (<a href="./references#CD010703-bbs2-0056" title="NCT02456532 . Safety and efficacy of chronic hypnotic use 2 (CIS2). clinicaltrials.gov/ct2/show/NCT02456532 (first received 28 May 2015). ">NCT02456532</a>). </p> </section> <section id="CD010703-sec-0085"> <h5 class="title">Studies awaiting classification</h5> <p>A total of six studies have been identified as 'awaiting classification'.</p> <p>The search in February 2016 identified four RCTs (<a href="./references#CD010703-bbs2-0052" title="NCT00392041 . Eszopiclone in the treatment of insomnia and associated symptoms of fibromyalgia. clinicaltrials.gov/ct2/show/NCT00392041 (first received 25 October 2006). ">NCT00392041</a>; <a href="./references#CD010703-bbs2-0053" title="EUCTR2006‐001529‐24[HU , AT , GB , FR] . Adults administered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31‐Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co‐administered with Venlafaxine in Subjects with Major Depressive Disorder (MDD) and Co‐existing Insomnia. https://www.clinicaltrialsregister.eu/2006. NCT00435279 . A 31‐week, efficacy, safety and tolerability study of eszopiclone 3 mg co‐administered with venlafaxine in subjects with major depressive disorder (MDD) and co‐existing insomnia. clinicaltrials.gov/ct2/show/NCT00435279 (first received 14 February 2007). ">NCT00435279</a>; <a href="./references#CD010703-bbs2-0051" title="NCT00374556 . The efficacy of eszopiclone (Lunesta) for chronic insomnia associated with osteoarthritis. clinicaltrials.gov/ct2/show/NCT00374556 (first received 11 September 2006). ">NCT00374556</a>; <a href="./references#CD010703-bbs2-0054" title="NCT01100164 . A Non‐inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg ‐ for the Treatment of Insomnia (Eszo). https://clinicaltrials.gov/ct2/show/NCT011001642010. PintoLRJr , BittencourtLR , TreptowEC , BragaLR , TufikS . Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (Sao Paulo)2016; Vol. 71, issue 1:5‐9. ">Pinto 2016/</a>NCT01100164) with a completed or unknown recruitment status in registry databases (<a href="http://www.who.int/ictrp/" target="_blank">WHO trials portal</a>; <a href="http://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>); no study publications were identified at this time. Accordingly, eligibility of the trials could not be conclusively assessed on the basis of published materials and requests to investigators. These studies included RCTs on eszopiclone in the treatment of insomnia associated with fibromyalgia (<a href="./references#CD010703-bbs2-0052" title="NCT00392041 . Eszopiclone in the treatment of insomnia and associated symptoms of fibromyalgia. clinicaltrials.gov/ct2/show/NCT00392041 (first received 25 October 2006). ">NCT00392041</a>), with major depressive disorder (<a href="./references#CD010703-bbs2-0053" title="EUCTR2006‐001529‐24[HU , AT , GB , FR] . Adults administered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31‐Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co‐administered with Venlafaxine in Subjects with Major Depressive Disorder (MDD) and Co‐existing Insomnia. https://www.clinicaltrialsregister.eu/2006. NCT00435279 . A 31‐week, efficacy, safety and tolerability study of eszopiclone 3 mg co‐administered with venlafaxine in subjects with major depressive disorder (MDD) and co‐existing insomnia. clinicaltrials.gov/ct2/show/NCT00435279 (first received 14 February 2007). ">NCT00435279</a>), with osteoarthritis (<a href="./references#CD010703-bbs2-0051" title="NCT00374556 . The efficacy of eszopiclone (Lunesta) for chronic insomnia associated with osteoarthritis. clinicaltrials.gov/ct2/show/NCT00374556 (first received 11 September 2006). ">NCT00374556</a>), and of primary insomnia according to DSM‐4 (<a href="./references#CD010703-bbs2-0054" title="NCT01100164 . A Non‐inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg ‐ for the Treatment of Insomnia (Eszo). https://clinicaltrials.gov/ct2/show/NCT011001642010. PintoLRJr , BittencourtLR , TreptowEC , BragaLR , TufikS . Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (Sao Paulo)2016; Vol. 71, issue 1:5‐9. ">Pinto 2016</a>). Accordingly, the eligibility of the studies will be checked again in updates of the review. </p> <p>The update search in February 2018 identified a further two studies awaiting classification (<a href="./references#CD010703-bbs2-0049" title="BaranB , DemanueleC , VuperTC . The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a double‐blind randomised trial. Sleep Conference: 31st Anniversary Meeting of the Associated Professional Sleep Societies, LLC, SLEEP. United States, 2017; Vol. 40:A415. ">Baran 2017</a>) and (<a href="./references#CD010703-bbs2-0050" title="BuxtonOM , PavlovaMK , O'ConnorSP , WangW , WinkelmanJW . Lack of change in glucose metabolism in eszopiclone‐treated primary insomnia patients. Nature and Science of Sleep2017;9:187‐98. ">Buxton 2017</a>) (see <a href="#CD010703-sec-0066">Results of the search</a>). </p> </section> </section> </section> <section id="CD010703-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p>For details of the risk of bias judgements for each study, see <a href="./references#CD010703-sec-0144" title="">Characteristics of included studies</a>. Graphical representations of the overall risk of bias in included studies are presented in <a href="#CD010703-fig-0002">Figure 2</a> and <a href="#CD010703-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010703-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010703-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010703-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010703-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010703-sec-0087"> <h4 class="title">Allocation</h4> <section id="CD010703-sec-0088"> <h5 class="title">Sequence generation</h5> <p>Methods used for sequence generation were specified in two RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), describing the generation of the random allocation schedule as being based on an internet randomisation system (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>) and a computer‐driven pseudo‐random number generator (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>). Accordingly, methods used for sequence generation were rated as being adequate in two RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>) and unclear for the remaining 12 studies. </p> </section> <section id="CD010703-sec-0089"> <h5 class="title">Allocation concealment</h5> <p>Randomisation was described as centralised and conducted by an independent support unit remote from participant recruitment centres in three RCTs (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a> additionally reported that drug capsules were supplied by the sponsor in sequentially numbered pill containers and that the random allocation sequence was only provided to the investigators after all subjects had completed the study. The remaining 11 RCTs did not specify methods used for allocation concealment. Applying our criteria for adequate allocation concealment (centralised drug preparation performed remote from the participant recruitment), risk of bias in the randomisation process was rated as being low in three of 14 RCTs (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). </p> </section> <section id="CD010703-sec-0090"> <h5 class="title">Baseline equivalence</h5> <p>Baseline equivalence for age, gender, and indicators of sleep initiation and maintenance are were confirmed in 10 of 14 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>) and in one trial (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), gender differences between treatment groups were detected, but adequately controlled in the statistical analyses. In all RCTs including insomnia associated with comorbid conditions, baseline equivalence for comorbid symptoms was tested and confirmed (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) or, if differences were shown (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>), these were controlled in the statistical analyses. All in all, three RCTs did not fulfil our criteria for baseline equivalence (baseline equivalence or control for age, gender, sleep initiation, sleep maintenance, and comorbidity), including two RCTs (<a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>), which did either not provide information on gender or baseline sleep initiation and one RCT (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>) identifying a significant group difference for sleep latency at baseline, which was not reported to be controlled. </p> </section> </section> <section id="CD010703-sec-0091"> <h4 class="title">Blinding</h4> <p>Blinding integrity was described as being tested and confirmed in one trial (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), and two trials (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>) tested adherence and treatment success of participants who perceived an unpleasant taste and found consistent results for the entire sample. Accordingly, the risk of unmasking blinding was rated as being low in three RCTs (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>), while for the remaining 11 RCTs, the risk was judged as being uncertain. </p> </section> <section id="CD010703-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>Two RCTs included in the review did not provide information on the principles of analysis used in the study (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>) or applied further criteria such as compliance at least five days per week for the first two weeks (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>). For the remaining 12 of 14 RCTs, it was reported that statistical analyses were conducted according to the intention‐to‐treat principle, analysing all randomised participants (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>) or those who have received at least one dose of treatment (treatment‐received analysis; <a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) in the group they had been allocated to by randomisation. When analysing the ITT (intention‐to‐treat) population comprising all randomised participants, the last‐observation‐carried‐forward (LOCF) technique was used to impute missing data in seven studies (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). All in all, 12 of 14 RCTs (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) met our criteria for an adequate handling of incomplete outcome data. </p> </section> <section id="CD010703-sec-0093"> <h4 class="title">Selective reporting</h4> <p>Outcomes listed in the methods section were adequately reported and properly interpreted in all but one trial (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), which mentioned TST during the run‐out period as a secondary outcome in the methods section, but did not provide results in the result section. All trials included in the review considered both indicators of sleep induction and sleep maintenance as primary or secondary endpoints. Nevertheless, outcome diversity was limited in two trials (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>), which had a study duration assumed to be sufficient to conclusively assess withdrawal and rebound insomnia, while these variables had not been assessed or at least reported as being assessed. Accordingly, 11 of 14 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) fulfilled our criteria of adequate outcome reporting and outcome diversity. </p> </section> <section id="CD010703-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010703-sec-0095"> <h5 class="title">Performance bias</h5> <p>Nine of 14 RCTs tested and confirmed the equivalence of medication compliance between groups (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), while the remaining five RCTs (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>) did not provide such information. With the exception of one trial (<a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>), studies permitting comedication for comorbid conditions tested and confirmed the equivalence of medication for comorbid conditions between groups (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>); in two of the comorbidity studies with the option of dose titration for antidepressive comedication (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>), differences in titrations were tested between groups. The use of further medication was allowed in some studies (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>); three of these (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) compared the use of concomitant medication and confirmed the equivalence between groups. All trials including elderly participants (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) compared daytime napping between groups to control for the occurrence of compensatory sleep. Applying all criteria for an equivalent treatment utilisation (equivalence of medication compliance, use of further medications and daytime napping) simultaneously, six of 14 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) were rated to have a low risk of performance bias. </p> </section> <section id="CD010703-sec-0096"> <h5 class="title">General susceptibility to bias</h5> <p>Eleven of 14 RCTs assessed sleep efficacy outcomes exclusively on the basis of participant reports using an electronic sleep diary (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>), paper sleep diary (<a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>), or interactive voice response system (IVRS; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), while three RCTs <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) combined self‐report measures with polysomnography (PSG) (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) and actigraphy recording (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>). Thus, susceptibility to bias effects for sleep outcomes was rated as being low for three of 14 RCTs (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>) and as being uncertain for the remaining 11 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). With the exception of one RCT (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), which assessed next‐day functioning by self‐reports and the Digit‐Symbol Substitution Test (DSST), RCTs included in the review measured functioning during the next day on the basis of participant reports. Accordingly, susceptibility to bias effects for next‐day functioning was rated as being low in <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> and as being uncertain in the remaining 13 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). </p> </section> <section id="CD010703-sec-0097"> <h5 class="title">Publication bias</h5> <p>By plotting of the mean differences against their standard error for the primary efficacy outcomes SOL (<a href="#CD010703-fig-0004">Figure 4</a>) and WASO (<a href="#CD010703-fig-0005">Figure 5</a>), we did not identify asymmetry, but note that the interpretation of funnel plot graphs was impeded by the small number of included studies, limiting the conclusiveness of the funnel plot method. </p> <div class="figure" id="CD010703-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.1 Sleep onset latency (SOL)." data-id="CD010703-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.1 Sleep onset latency (SOL). </p> </div> </div> </div> <div class="figure" id="CD010703-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.2 Wake time after sleep onset (WASO)." data-id="CD010703-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.2 Wake time after sleep onset (WASO). </p> </div> </div> </div> </section> </section> </section> <section id="CD010703-sec-0098"> <h3 class="title" id="CD010703-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD010703-tbl-0001"><b>Summary of findings for the main comparison</b> Eszopiclone for insomnia</a> </p> <section id="CD010703-sec-0099"> <h4 class="title">Comparison 1: Eszopiclone versus placebo</h4> <p>Of 14 RCTs included in the review, 13 RCTs contributed to the meta‐analysis. One RCT (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>) provided statistics for repeated measures mixed model analyses, which could not be integrated into meta‐analyses. From the two RCTs using a three‐armed design (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), only the study arms with eszopiclone under recommended dosing (3 mg for non‐elderly, 2 mg for elderly participants) and placebo were included. Results for the primary and secondary outcomes of the review are described below and outlined for the most important findings in the <a href="./full#CD010703-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD010703-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD010703-sec-0101"> <h6 class="title">1.1 Sleep onset latency (SOL)</h6> <p>Meta‐analyses of participant‐reported data show that eszopiclone significantly decreased length of time after lights‐out until sleep by approximately 12 minutes (Mean Difference (MD) ‐11.94 min, 95% confidence interval (CI) ‐16.03 to ‐7.86; participants = 2890; studies = 9; I<sup>2</sup> = 0%; moderate quality evidence; <a href="./references#CD010703-fig-0006" title="">Analysis 1.1</a>) compared to placebo. </p> </section> <section id="CD010703-sec-0102"> <h6 class="title">1.2 Wake time after sleep onset (WASO)</h6> <p>Compared to placebo, eszopiclone significantly reduced participant‐reported wake time after sleep onset by about 17 minutes (MD ‐17.02 min, 95% CI ‐24.89 to ‐9.15; participants = 2295; studies = 8; I<sup>2</sup> = 55%; moderate quality evidence; <a href="./references#CD010703-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD010703-sec-0103"> <h6 class="title">1.3 Withdrawal symptoms</h6> <p>Following drug discontinuation during single‐blind placebo run‐out periods, a total of 22 new or deteriorated adverse events were documented from seven RCTs with 3125 participants (<a href="./references#CD010703-fig-0008" title="">Analysis 1.3</a>). The overall risk of being affected by withdrawal symptoms did not differ between the eszopiclone and the placebo group (RD 0.00, 95% CI ‐0.03 to 0.04; participants = 2103; studies = 5; I<sup>2</sup> = 42%). Accidental injury, agitation, anxiety, back pain, dizziness, headache, nausea, pharyngitis, and pain were listed in more than one study, with headache being the most frequently reported symptom (RD 0.00, 95% CI ‐0.01 to 0.01; participants = 2237; studies = 6; I<sup>2</sup> = 0%; <a href="./references#CD010703-fig-0008" title="">Analysis 1.3</a>). Nevertheless, for the 22 adverse events reported during the single‐blind placebo run‐out, the risk difference was not shown to significantly differ between groups. </p> </section> <section id="CD010703-sec-0104"> <h6 class="title">1.4 Rebound insomnia</h6> <p>Mean change from baseline values for the primary efficacy outcomes SOL (MD 17.00 min, 95% CI ‐4.29 to 38.29; participants = 291; studies = 1; I<sup>2</sup> and T<sup>2</sup>: not applicable; low quality evidence) and WASO (MD ‐6.71, 95% CI ‐21.25 to 7.83; participants = 291; studies = 1; I<sup>2</sup> and T<sup>2</sup>: not applicable; low quality evidence) averaged over the first three nights of the single‐blind run‐out period did not indicate worsening of sleep after drug discontinuation (<a href="./references#CD010703-fig-0009" title="">Analysis 1.4</a>). Negative signs of change from baseline values, shown for each single night during the discontinuation period in the eszopiclone group as well as the placebo group (data not shown), indicated that hypnotic efficacy measures improved after treatment, irrespective of treatment condition. </p> </section> </section> <section id="CD010703-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD010703-sec-0106"> <h6 class="title">1.5 Total sleep time (TST)</h6> <p>Compared to placebo, eszopiclone significantly increased total sleep time by about 28 minutes (MD 27.70 min, 95% CI 20.30 to 35.09; participants = 2965; studies = 10; I<sup>2</sup> = 39%; moderate quality evidence; <a href="./references#CD010703-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD010703-sec-0107"> <h6 class="title">1.6 Next‐day alertness</h6> <p>Meta‐analytic results showed that next‐day alertness during double‐blind treatment was rated as being significantly higher in the eszopiclone than in the placebo group (MD 0.46, 95% CI 0.28 to 0.63; participants = 2061; studies = 8; I<sup>2</sup> = 31%; low quality evidence; <a href="./references#CD010703-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD010703-sec-0108"> <h6 class="title">1.7 Adverse events</h6> <p>Compared to participants in the placebo group, participants treated with eszopiclone did not significantly differ in their risk of dropping out from treatment due to adverse events (RD 0.01, 95% CI ‐0.01 to 0.02; participants = 4007; studies = 11; I<sup>2</sup> = 52%; moderate quality evidence; <a href="./references#CD010703-fig-0012" title="">Analysis 1.7</a>). Among a total of 34 adverse events, headache (n = 10), unpleasant taste (n = 9) and somnolence (n = 8) were most commonly reported, followed by accidental injury and dizziness (n = 7) as well as and back pain and dry mouth (each reported in six RCTs). Significant risk differences were demonstrated for unpleasant taste (RD 0.18, 95% CI 0.14 to 0.21; NNTH = 5.6, 95% CI 4.8 to 7.1; participants = 3787; studies = 9; I<sup>2</sup> = 72%), dry mouth (RD 0.04, 95% CI 0.02 to 0.06; NNTH = 25, 95% CI 16.7 to 50.0; participants = 2802; studies = 6; I<sup>2</sup> = 11%), somnolence (RD 0.04, 95% CI 0.02 to 0.06; NNTH = NNTH = 25, 95% CI 16.7 to 50.0; participants = 3532; studies = 8; I<sup>2</sup> = 10%) and dizziness (RD 0.03, 95% CI 0.01 to 0.05; NNTH = 33.3, 95% CI 20.0 to 100.0; participants = 2933; studies = 7; I<sup>2</sup> = 48%). </p> <p>Serious adverse events occurred in eight of 12 RCTs (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). There was no significant difference between groups in the occurrence of serious adverse events (RD 0.00, 95% CI ‐0.01 to 0.01; participants = 4289; studies = 12; I<sup>2</sup> = 0%; T<sup>2</sup> = 0.00). Serious adverse events observed in the eszopiclone groups included suicide and death due to arteriosclerotic heart disease (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>), anxiety and confusion (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>), gastrointestinal disorder (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>), moderate to severe chest pain (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), accidental injury due to a fall (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>), asthma, cholelithiasis, concussion with multiple fractures and loss of consciousness (<a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>) and cerebrovascular accident (<a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>). With the exception of one RCT, in which serious adverse events in 0.34% of participants (2/593) taking eszopiclone over the 6‐month treatment were considered to be “possibly related” to therapy (<a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>), serious adverse events in further trials were not considered by the investigators to be treatment‐related. Also, where accidental injury due to a fall occurred two days after the end of treatment (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>) or due to slipping on a wet floor in the late afternoon (<a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>), investigators classified these serious events as unrelated to treatment. </p> </section> </section> </section> <section id="CD010703-sec-0109"> <h4 class="title">Subgroup analyses</h4> <section id="CD010703-sec-0110"> <h5 class="title">Primary versus comorbid insomnia</h5> <p>Subgroup analyses for different types of insomnia showed significant effects for eszopiclone in samples with primary insomnia (SOL: MD ‐15.14 minutes, 95% CI ‐21.13 to ‐9.15; participants = 1803; studies = 5; I<sup>2</sup> = 0%; WASO: MD ‐15.76 min, 95% CI ‐25.60 to ‐5.92; participants = 1803; studies = 5; I<sup>2</sup> = 68%; TST: MD 30.04 min, 95% CI 19.09 to 40.98; participants = 1878; studies = 6; I<sup>2</sup> = 52%) and comorbid insomnia as well (WASO: MD ‐21.20 min, 95% CI ‐40.76 to ‐1.65; participants = 462; studies = 2; I<sup>2</sup> = 36%; TST: MD 23.37 min, 95% CI 12.61 to 34.12; participants = 462; studies = 2; I<sup>2</sup> = 0%), except for SOL, which did not reach statistical significance in the comorbid insomnia sample (SOL: MD ‐8.10 min, 95% CI ‐17.77 to 1.57; participants = 462; studies = 2; I<sup>2</sup> = 24%). </p> <p>Sleep efficacy outcomes, separately analysed for primary insomnia and comorbid insomnia subgroups, are shown in <a href="./references#CD010703-fig-0013" title="">Analysis 1.8</a> for SOL, <a href="./references#CD010703-fig-0014" title="">Analysis 1.9</a> for WASO, and <a href="./references#CD010703-fig-0015" title="">Analysis 1.10</a> for TST. </p> </section> <section id="CD010703-sec-0111"> <h5 class="title">Young to middle‐aged versus older age</h5> <p>Analyses for the subgroups of young to middle‐aged and older age individuals demonstrated significant effects in samples aged between 18 to 64 years (SOL: MD ‐13.08 minutes, 95% CI ‐19.15 to ‐7.00; participants = 2049; studies = 5, I<sup>2</sup> = 25%; WASO: MD ‐12.20 minutes, 95% CI ‐19.02 to ‐5.37; participants = 1454; studies = 4; I<sup>2</sup> = 5%; TST: MD 29.66 minutes, 95% CI 21.60 to 37.72; participants = 2124; studies = 6; I<sup>2</sup> = 30%) and samples with an age over 64 years (SOL: MD ‐11.41 minutes, 95% CI ‐20.37 to ‐2.45; participants = 811; studies = 3; I<sup>2</sup> = 0%; WASO: MD ‐22.16 minutes, 95% CI ‐40.70 to ‐3.63; participants = 811; studies = 3; I<sup>2</sup> = 81%; TST: MD 27.01 minutes, 95% CI 11.83 to 42.18; participants = 811; studies = 3; I<sup>2</sup> = 49%). Sleep efficacy outcomes separately analysed for different age subgroups are shown in <a href="./references#CD010703-fig-0013" title="">Analysis 1.8</a> for SOL, <a href="./references#CD010703-fig-0014" title="">Analysis 1.9</a> for WASO, and <a href="./references#CD010703-fig-0015" title="">Analysis 1.10</a> for TST. </p> <p>Next‐day alertness was significantly increased by 0.56 points on the 11‐point Likert scale in young to middle‐aged individuals (MD 0.56, 95% CI 0.37 to 0.75; participants = 1220; studies = 4; I<sup>2</sup> = 0%) and 0.34 points in the elderly (MD 0.34, 95% CI 0.01 to 0.67; participants = 811; studies = 3; I<sup>2</sup> = 58%). Analyses of serious adverse events, limited to the subgroup of elderly participants, did not show a difference between the eszopiclone and placebo condition (RD 0.00, 95% CI ‐0.01 to 0.02; participants = 804; studies = 3; I<sup>2</sup> = 58%). Serious adverse events in the elderly included suicide and death due to arteriosclerotic heart disease (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>), moderate to severe chest pain (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>) and accidental injury due to a fall, which occurred two days after the end of treatment (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>) and was classified by the investigator as unrelated to treatment. Compared to participants in the placebo group, elderly participants treated with eszopiclone did not significantly differ in their risk of dropping out from treatment due to adverse events (RD ‐0.00, 95% CI ‐0.03 to 0.03; participants = 811; studies = 3; I<sup>2</sup> = 30%). Among a total of 19 adverse events reported in participants aged over 64 years, significant risk differences were demonstrated for unpleasant taste (RD 0.11, 95% CI 0.08 to 0.15; participants = 811; studies = 3; I<sup>2</sup> = 0%), dry mouth (RD 0.07, 95% CI 0.02 to 0.12; participants = 264; studies = 1), and dizziness (RD 0.03, 95% CI 0.01 to 0.06; participants = 652; studies = 2; I<sup>2</sup> = 0%). For an overview of adverse events analyses in elderly subgroups, see <a href="./references#CD010703-fig-0020" title="">Analysis 1.15</a>. </p> </section> <section id="CD010703-sec-0112"> <h5 class="title">Study initiation</h5> <p>Subgroup analyses for type of study initiation showed significant effects in investigator‐initiated trials (SOL: MD ‐8.29 minutes, 95% CI ‐14.24 to ‐2.34; participants = 677; studies = 3; I<sup>2</sup> = 0%) (WASO: MD ‐33.29 minutes, 95% CI ‐56.47 to ‐10.10; participants = 82; studies = 2; I<sup>2</sup> = 0%) and sponsor‐initiated trials (SOL: MD ‐15.21 min, 95% CI ‐20.83 to ‐9.59; participants = 2213; studies = 6; I<sup>2</sup> = 0%) (WASO: MD ‐15.31 min, 95% CI ‐23.50 to ‐7.11; participants = 2213; studies = 6; I<sup>2</sup> = 61%) (TST: MD 28.40 min, 95% CI 19.60 to 37.21; participants = 2288; studies = 7; I<sup>2</sup> = 48%), except for TST, which was not significant in investigator‐initiated trials (TST: MD 21.04 minutes, 95% CI ‐4.19 to 46.27; participants = 677; studies = 3; I<sup>2</sup> = 41%). </p> <p>Sleep efficacy outcomes, separately analysed for sponsor‐initiated versus investigator‐initiated, are shown in <a href="./references#CD010703-fig-0021" title="">Analysis 1.16</a> for SOL, <a href="./references#CD010703-fig-0022" title="">Analysis 1.17</a> for WASO and <a href="./references#CD010703-fig-0023" title="">Analysis 1.18</a> for TST. </p> </section> </section> <section id="CD010703-sec-0113"> <h4 class="title">Sensitivity analyses</h4> <section id="CD010703-sec-0114"> <h5 class="title">Assessment of sleep outcomes</h5> <p>Effect estimates based on objective assessment methods such as polysomnography and actigraphy were slightly lower in their magnitude (SOL: MD ‐15.50 min, 95% CI ‐19.89 to ‐11.11; participants = 468; studies = 2; WASO: MD ‐12.37 min, 95% CI ‐18.61 to ‐6.13; participants = 468; studies = 2; I<sup>2</sup> = 0%) (TST: MD 28.60 min, 95% CI 18.14 to 39.06; participants = 264; studies = 1) than participant‐reported outcomes, while still reaching statistical significance. Accordingly, the demonstration of effects of eszopiclone on sleep efficacy outcomes did not seem to depend on type of measurement (<a href="./references#CD010703-fig-0024" title="">Analysis 1.19</a>). </p> </section> <section id="CD010703-sec-0115"> <h5 class="title">Assessment of withdrawal</h5> <p>Withdrawal assessed with the BWSQ scale (SMD ‐0.06, 95% CI ‐0.26 to 0.14; participants = 1218; studies = 2) did not indicate a significant difference between the eszopiclone and placebo group, confirming the findings on reported events (<a href="./references#CD010703-fig-0025" title="">Analysis 1.20</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010703-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010703-sec-0116"></div> <section id="CD010703-sec-0117"> <h3 class="title" id="CD010703-sec-0117">Summary of main results</h3> <p>A total of 14 RCTs with 4732 participants were included in this review. Most RCTs included in the review covered short‐term (≤ four weeks; six RCTs) and medium‐term treatment with eszopiclone (&gt; four weeks ≤ six months; five RCTs), with three RCTs having a treatment duration of 12 months or more. Eszopiclone was provided in a dose of 3 mg for non‐elderly and 2 mg for elderly individuals. </p> <p>Meta‐analyses of participant‐reported data on sleep efficacy outcomes demonstrated a 12‐minute decrease of SOL, a 17‐minute decrease of WASO and an approximate 28‐minute increase of TST for eszopiclone compared to placebo. There were no significant changes from baseline to the first night after drug discontinuation for SOL and WASO in the majority of trials and no significant differences between groups in the prevalence of new or worsening adverse events. Participant‐reported data also indicated that next‐day alertness significantly improved under eszopiclone compared to placebo, while adverse events, documented significantly more frequently under eszopiclone compared to placebo, included unpleasant taste, dry mouth, somnolence, and dizziness. </p> <p>Subgroup analyses indicated that eszopiclone improved most sleep efficacy outcomes irrespective of insomnia type (primary and comorbid insomnia), age groups (young to middle‐aged and elderly individuals) and study initiation (investigator initiation and sponsor initiation). The statistical and qualitative integration of evidence from RCTS indicated moderate, but robust, therapeutic effects of eszopiclone on sleep efficacy outcomes. Nevertheless, safety should be determined on the base of individual risk patterns and monitored closely during treatment. </p> <p>When counterbalancing risks against benefits, a half an hour increase of sleep time per night might not seem much at first glance. However, it represents a mean value averaged over nights of poor sleep and good nights` sleep, both contributing to the night‐to‐night variability of sleep in insomniacs (<a href="./references#CD010703-bbs2-0213" title="VallièresA , IversH , BastienCH , Beaulieu‐BonneauS , MorinCM . Variability and predictability in sleep patterns of chronic insomniacs. Journal of Sleep Research2005;14(4):447‐53. ">Valieres 2005</a>). A limitation of eszopiclone intake to nights of poor sleep according to 'treatment as needed' can be expected to clearly exceed demonstrated effects. Intermittent dosing or 'treatment as needed' with eszopiclone might be an alternative to daily scheduled treatment and bring about advantages in terms of habituation and discontinuation effects that has to be tested in further trials. </p> </section> <section id="CD010703-sec-0118"> <h3 class="title" id="CD010703-sec-0118">Overall completeness and applicability of evidence</h3> <p>Through including insomnia as a primary or a comorbid condition, the review concerns a wide range of insomniac problems and approximates the distribution of insomniac conditions in the general population (<a href="./references#CD010703-bbs2-0134" title="KatzDA , McHorneyCA . Clinical correlates of insomnia in patients with chronic illness. Archives of Internal Medicine1998;158(10):1099–1107. ">Katz 1998</a>). In addition, with a mean age between 40 and 50 years and the percentage of women varying between 63% and 67%, the distribution of age and gender in the primary studies corresponds with the larger insomnia population (<a href="./references#CD010703-bbs2-0081" title="DelahayeC , FerrandB , PieddeloupC , MuschB . Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice. International Clinical Psychopharmacology1990;5 Suppl(2):131‐8. ">Delahaye 1990</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). Contextual factors, such as length of treatment and comedications use, further contribute to the variety of treatment conditions. Nevertheless, due to reasons of safety and accessibility, certain subgroups of individuals might be underrepresented in clinical studies with eszopiclone. This concerns elderly participants with cognitive and psychomotor impairments, shown to have an increased risk for falls, serious injury, and hip fractures (<a href="./references#CD010703-bbs2-0067" title="BerrySD , LeeY , CaiS , DoreDD . Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Internal Medicine2013;173(9):754‐61. ">Berry 2013</a>) and individuals with substance use disorder, who might be at increased risk of using eszopiclone in an unrecommended way. Further limitations in the external validity might arise from the cultural context of clinical research. With the exception of one trial (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>), study sites were exclusively located in the United States. Even though post hoc analyses of studies with eszopiclone indicated the generalisability of findings across different ethnicities (<a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a>), cultural differences in values, norms, and health‐related beliefs might play a role in treatment utilisation, length of use, dosing, and compliance. With placebo as a comparator, integrated evidence on eszopiclone is only applicable to therapeutic decisions that concern eszopiclone versus 'no treatment', while for recommendations concerning the relative efficacy and safety of eszopiclone compared to other available interventions, no direct evidence is available. </p> <p>All in all, the nonrestrictive definition of inclusion criteria in terms of comorbidity, gender, age, and treatment conditions contributes to the external validity of the review and increases the applicability of findings to everyday clinical practice. Limitations in the variability of participant characteristics and treatment conditions originating from the cultural context, criteria of inclusion, differences in accessibility to clinical research and the monitoring of treatment implementation in clinical trials, have to be taken into consideration when determining the applicability of evidence. Thus, a weighting of risks and benefits for prescribing eszopiclone has always been made against the background of individual participant characteristics, particularly those associated with a patients' vulnerability to adverse events and those influencing medication‐taking behaviour. As placebo was the only comparator considered in RCTs with eszopiclone, available evidence did not allow conclusions on the superiority or inferiority of eszopiclone compared to alternative therapeutic options. </p> </section> <section id="CD010703-sec-0119"> <h3 class="title" id="CD010703-sec-0119">Quality of the evidence</h3> <p>Applying GRADE criteria for down‐ and upgrading the quality of evidence, we rated the overall quality as being moderate for sleep efficacy outcomes and adverse events and as being low for rebound effects and next‐day functioning. We downgraded quality to moderate because of threats to bias resulting from incomplete reporting of certain design features and unmatched taste of eszopiclone. Downgrading quality of evidence for rebound insomnia to a low grade was based on the poor study design of most studies for assessing discontinuation effects, while for next‐day functioning, the assumed inadequacy of subjective reporting for representing clinically relevant qualities of functioning caused downgrading of the evidence. Thus, due to methodological limitations, such as the open‐label design of run‐out intervals in some trials and a potential lack of sensitivity to subjective measures for detecting psychomotor and cognitive impairments, safety conclusions of the review concerning rebound insomnia and next‐day functioning might be of limited validity. Quality rating for each outcome is shown in the summary of findings table (<a href="./full#CD010703-tbl-0001">summary of findings Table for the main comparison</a>), and the rating of single GRADE criteria for downgrading (risk of bias, inconsistency, indirectness, imprecision, publication bias) is outlined in detail in the following. </p> <section id="CD010703-sec-0120"> <h4 class="title">Risk of bias: efficacy outcomes</h4> <p>Various design characteristics of the RCTs included in the review ensured the methodological quality of evidence. Most studies (12 of 14 RCTs) stated that participants were randomly assigned to treatment groups to prevent selection bias and to ensure equivalence between groups at baseline, and treatment and placebo groups were compared for age, gender and for indicators of sleep initiation and sleep maintenance (11 of 14 RCTs). All participants, or at least those who have received at least one dose of treatment, were analysed in the group they had been allocated to by randomisation (12 of 14 RCTs) to avoid attrition bias, while the risk of performance bias was limited by ensuring the equivalence between groups in the use of concomitant medication for comorbid disorders (seven of eight RCTs), in the use of substances with a secondary effect on sleep (three of six RCTs) and in medication compliance (nine of 14 RCTs). In addition, all RCTs including elderly participants compared treatment groups for daytime napping to control the occurrence of compensatory sleep as a further risk of performance bias. Outcomes listed in the method sections were adequately reported and properly interpreted and all RCTs included in the review considered both indicators of sleep induction and sleep maintenance as endpoints of the statistical analyses at the same time. </p> <p>Despite these measures, some uncertainties persisted. Since specific features of the study design were omitted from most trial reports, it remained unclear whether these had not been implemented or whether these had been implemented, but not reported. Frequently omitted information concerned the specification of methods used for sequence generation, allocation concealment, and blinding procedures. Unclear concealment, has repeatedly been shown to be associated with bias effects in various fields of clinical research (<a href="./references#CD010703-bbs2-0128" title="Huwiler‐MuntenerK , JuniP , JunkerC , EggerM . Quality of reporting of randomised trials as a measure of methodologic quality. Journal of the American Medical Association2002;287(21):2801‐4. ">Huwiler‐Muntener 2002</a>; <a href="./references#CD010703-bbs2-0176" title="PildalJ , HrobjartssonA , JorgensenKJ , HildenJ , AltmanDG , GotzschePC . Impact of allocation concealment on conclusions drawn from meta‐analyses of randomized trials. International Journal of Epidemiology2007;36(4):847‐57. ">Pildal 2007</a>; <a href="./references#CD010703-bbs2-0198" title="SchulzKF . Subverting randomization in controlled trials. Journal of the American Medical Association1995;274(18):1456‐8. ">Schulz 1995</a>). In addition, subject‐specific threats to bias might have arisen from eszopiclone`s unpleasant taste, which was reported by a considerable proportion of participants treated with eszopiclone (see <a href="#CD010703-tbl-0003">Table 2</a>). Drug characteristics, revealing the identity of medication to participants or investigators and their impact on estimates of efficacy, have strikingly been shown in the example of antidepressants drugs (<a href="./references#CD010703-bbs2-0162" title="MoncrieffJ , WesselyS , HardyR . Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD003012.pub2] ">Moncrieff 2004</a>). Even though perception of unpleasant taste has not been significantly associated with treatment adherence or success in selected studies (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>), the evidence removed all doubts. Accordingly, we downgraded the quality of evidence to a moderate degree for sleep efficacy outcomes and adverse events<i>.</i> </p> <div class="table" id="CD010703-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates of unpleasant taste</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESZ (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PBO (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.03</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ESZ: eszopiclone</sup> </p> <p><sup>PBO: placebo</sup> </p> </div> </div> </section> <section id="CD010703-sec-0121"> <h4 class="title">Risk of bias: rebound effects</h4> <p>For rating the quality of evidence on discontinuation effects, methodological features of the interval subsequent to the randomised controlled treatment period were taken into consideration. Seven of the 12 RCTs exceeding the threshold duration of two weeks for assessing discontinuation effects applied a single‐blind placebo run‐out period to assess change from baseline for sleep efficacy outcomes, while the remaining five RCTs (with a duration &gt; two weeks) applied open‐label extensions, naturalistic follow‐up, or no follow‐up. Considering the latter as not being appropriate for controlling bias effects, we downgraded the quality of evidence for rebound insomnia outcomes to a low degree. </p> </section> <section id="CD010703-sec-0122"> <h4 class="title">Inconsistency</h4> <p>Even though some inconsistency of results has been shown for the primary efficacy outcome WASO, heterogeneity appeared to be mainly attributable to one trial (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), whose exclusion resulted into a I<sup>2</sup> reduction from 55% to 6%. Additionally, considering the low to moderate heterogeneity of results shown for further outcomes of the review (SOL: 0%; serious adverse events: 0%; TST: 31%; next‐day alertness: 31%), consistency of results was considered as not being serious. </p> </section> <section id="CD010703-sec-0123"> <h4 class="title">Indirectness</h4> <p>With placebo as a comparator, integrated evidence on eszopiclone was only applicable to therapeutic decisions that concerned eszopiclone versus 'no treatment', while for recommendations concerning the relative efficacy and safety of eszopiclone compared to other available interventions, no direct evidence was available. On the other hand, study samples, features of the therapeutic interventions (duration, dosing, etc.), and outcomes of the RCTs included in the review contributed to the directness of evidence in terms of population, intervention, comparator and efficacy outcomes, not raising considerable uncertainty about the applicability of the evidence to the relevant questions of daily practice. Thus, we did not rate limitations in directness of evidence as being serious for sleep efficacy outcomes and discontinuation effects. In contrast, we downgraded evidence due to indirectness for subjective next‐day functioning. In contrast to subjective efficacy outcomes, it was expected that the objective rather than the subjective measures of next‐day functioning might have determined the risk of harm, including injuries and accidents. Thus, questioning the clinical relevance of subjective next‐day functioning (compared to objective measures only applied in one RCT), we rated the directness of evidence for next‐day functioning as being limited and downgraded the evidence for next‐day functioning to low‐quality. </p> </section> <section id="CD010703-sec-0124"> <h4 class="title">Imprecision</h4> <p>Eleven of 14 RCTs included in the review were multicentre trials based on large study samples that allowed precise estimations of eszopiclone`s efficacy and safety; thus we did not judge the quality of evidence to be lowered by imprecision. </p> </section> <section id="CD010703-sec-0125"> <h4 class="title">Publication and funding bias</h4> <p>With the exception of two non‐profit funded RCTs (<a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>), trials included in the review were financially supported by the pharmaceutical industry. As subgroup analyses according to 'sponsoring type' would not be conclusive, due to the imbalance of sample size between non‐profit sponsored (two RCTs) and industry‐sponsored (10 RCTs) subgroups, we formed subgroups according to the type of study initiation. Comparisons of effects from investigator‐ versus sponsor‐initiated trials did not demonstrate statistically significant differences (<a href="./references#CD010703-fig-0021" title="">Analysis 1.16</a>; <a href="./references#CD010703-fig-0022" title="">Analysis 1.17</a>; <a href="./references#CD010703-fig-0023" title="">Analysis 1.18</a>). Plotting of the mean differences against standard errors for SOL (<a href="#CD010703-fig-0004">Figure 4</a>) and WASO (<a href="#CD010703-fig-0005">Figure 5</a>) did not indicate asymmetry, but, due to the small number of included studies, the conclusiveness of the funnel plot method was limited (see <a href="#CD010703-sec-0094">Other potential sources of bias</a>). Nevertheless, a suspicion of funding bias (<a href="./references#CD010703-bbs2-0143" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Brisitsh Medical Journal2003;31(326):1167‐70. ">Lexchin 2003</a>) remained due to the overweight of industry‐sponsored trials. </p> </section> </section> <section id="CD010703-sec-0126"> <h3 class="title" id="CD010703-sec-0126">Potential biases in the review process</h3> <p>Even though, according to the standards of the Cochrane Collaboration, various strategies have been implemented in the planning and conduction of the review to limit bias in the review process and to increase research transparency, a number of methodological decisions were left to the authors and are discussed for their impact on efficacy and safety conclusions of the review in the following comments. </p> <p>We decided to exclude studies with a cross‐over design due to the fact that sleep stabilising effects of eszopiclone have been reported even after drug discontinuation (<a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), making it difficult to control carry‐over effects by wash‐out. We identified two studies with a cross‐over design fulfilling further inclusion criteria of our review (<a href="./references#CD010703-bbs2-0021" title="ErmanMK , ZammitG , RubensR , SchaeferK , WesselT , AmatoD , et al. A polysomnographic placebo‐controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. Journal of Clinical Sleep Medicine2008;4(3):229‐34. ">Erman 2008</a>; <a href="./references#CD010703-bbs2-0024" title="JoffeH , PetrilloL , VigueraA , KoukopoulosA , Silver‐HeilmanK , FarrellA , et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomised, double‐blinded, placebo‐controlled crossover trial. American Journal of Obstetrics &amp; Gynecology2010;202(2):171.e1‐171.e11. ">Joffe 2010</a>), both confirming the sleep‐promoting effects of eszopiclone. Accordingly, we assumed that our decision to include parallel group studies was unlikely to have affected the efficacy and safety conclusions of the review. </p> <p>Treatment effectiveness was assessed through two outcomes: 1. 'sleep onset latency' (SOL) defined as the length of time (in minutes) after lights‐out until sleep onset, and 2. 'wake time after sleep onset' (WASO), defined as the length of time (in minutes) of wakefulness after the onset of persistent sleep. The consideration of two effectiveness outcomes was reasoned by their conceptual distinctiveness, with SOL measuring a drug's impact on sleep onset, and WASO measuring its potential to improve sleep maintenance. Thereby, the former reflected its suitability for the treatment of sleep‐onset insomnia and the latter for sleep‐maintenance insomnia (see <a href="#CD010703-sec-0031">Description of the condition</a>). Even though assessed on the base of conceptual distinctive outcomes, sleep efficacy outcomes of the review might not have captured the full extent of insomnia. Nevertheless, to control for Type I error and to ensure clarity and comprehensibility of the review, outcomes were limited on the base of theoretical considerations. </p> <p>A further important methodological decision concerned the 'type of participants' considered as eligible for the review. The original protocol had limited 'type of participants' to patients with primary insomnia. A careful weighing of the available evidence and a reconsideration of the referees` comments made us extend the inclusion criteria by including both primary and secondary insomnia. Our arguments for doing so are outlined in the section <a href="#CD010703-sec-0142">Differences between protocol and review</a>. Primary and comorbid insomnia was considered as criteria for subgroup analyses (<a href="./references#CD010703-fig-0013" title="">Analysis 1.8</a>; <a href="./references#CD010703-fig-0014" title="">Analysis 1.9</a>; <a href="./references#CD010703-fig-0015" title="">Analysis 1.10</a>), allowing a statistical analysis of the impact that type of insomnia diagnosis had on efficacy outcomes of the review. </p> <p>A limitation arose from the asymmetric distribution of primary sleep efficacy data and the provision of outcome statistics as medians in some studies, which had to be excluded from pooling of continuous data (<a href="./references#CD010703-bbs2-0126" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;20(5):1‐10. ">Hozo 2005</a>). The problem marginally concerned sleep efficacy outcomes, provided as means in the majority of studies (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>; <a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a>; <a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a>; <a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a>; <a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>; <a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>), but affected rebound effects to a more considerable extent. Effect estimations for change from baseline during run‐out intervals were based on only one trial (<a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a>), while outcomes from the remaining trials were provided as medians (<a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a>; <a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a>; <a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>; <a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>) or p‐values (<a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a>; <a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a>). <a href="#CD010703-tbl-0004">Table 3</a> compared information of significance between studies providing means and medians. Only one trial (<a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a>), not included in the statistical pooling of data, found a small, non‐significant increase in WASO on day one and three of the run‐out period and a significant decrease in TST on day one. </p> <div class="table" id="CD010703-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of outcome: means and medians</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome statistic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep efficacy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Rebound insomnia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TST</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß, SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.008</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.04</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.071.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.01</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.01</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.01</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LPS: latency to persistent sleep</p> <p>Nr: not reported</p> <p>Ns: not statistically significant (no quantitative information provided)</p> <p>P: P value</p> <p>SOL: sleep onset latency</p> <p>TST: total sleep time</p> <p>WASO: wake time after sleep onset</p> <p><b>bold: not included in the meta‐analyses</b> </p> </div> </div> <p>A strength of the review might have come from the nonrestrictive definition of inclusion criteria and from analysing the impact of potentially effect‐determining factors on the basis of subgroup and sensitivity analyses. A further strength was owed to the support we received from the primary investigators and further experts (see <a href="#CD010703-sec-0131">Acknowledgements</a>), who checked the completeness of our study search and who provided feedback on design characteristics and outcome statistics. Nevertheless, no unpublished trials and data could be included. This, together with the overweight of industry‐sponsored studies, clearly increased the risk of overestimating effects due to funding bias (<a href="./references#CD010703-bbs2-0143" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Brisitsh Medical Journal2003;31(326):1167‐70. ">Lexchin 2003</a>). </p> <p>Finally, to limit the influence of reviewers interests and expectations, all outcome statistics were extracted by at least two reviewers independently (SR &amp; CE, CE &amp; RW), and disagreements were resolved in consensus discussions between three reviewers (SR, CE, RW). To additionally prevent confirmation bias (<a href="./references#CD010703-bbs2-0169" title="NickersonRS . Confirmation bias: a ubiquitous phenomenon in many guises. Review of General Psychology1998;2(2):175–220. ">Nickerson 1998</a>), at least one author, who had not been involved in insomnia research before, participated in each review step. </p> </section> <section id="CD010703-sec-0127"> <h3 class="title" id="CD010703-sec-0127">Agreements and disagreements with other studies or reviews</h3> <p>Efficacy conclusions of the review largely agree with those of previous reviews and meta‐analyses (<a href="./references#CD010703-bbs2-0074" title="BuscemiN , VandermeerB , FriesenC , BialyL , TubmanM , OspinaM , et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta‐analysis of RCTs. Journal of General Internal Medicine2007;22(9):1335‐50. ">Buscemi 2007</a>; <a href="./references#CD010703-bbs2-0127" title="Huedo‐MedinaTB , KirschI , MiddlemassJ , KlonizakisM , SiriwardenaAN . Effectiveness of non‐benzodiazepine hypnotics in treatment of adult insomnia: meta‐analysis of data submitted to the Food and Drug Administration. British Medical Journal2012;17(345):e8343. ">Huedo‐Medina 2012</a>; <a href="./references#CD010703-bbs2-0195" title="SateiaMJ , BuysseDJ , KrystalAD , NeubauerDN , HealdJL . Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med2017;13(2):307‐49. ">Sateia 2017</a>), suggesting that eszopiclone is an effective therapeutic option in the treatment of insomnia. With a reduction of SOL by about 12 minutes, a decrease of WASO by about 17 minutes and an increase of TST by about 28 minutes, effects are comparable in their magnitude with those shwon by <a href="./references#CD010703-bbs2-0195" title="SateiaMJ , BuysseDJ , KrystalAD , NeubauerDN , HealdJL . Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med2017;13(2):307‐49. ">Sateia 2017</a> for SOL and TST in the 2 mg eszopiclone dosing group (SOL: MD = ‐17.78; 95% CI ‐28.52 to ‐7.04; TST: MD = 27.53; 95% CI 18.29 to 36.76) and for WASO in the 3 mg dosing group (WASO: MD = ‐14.49; 95% CI ‐17.68 to ‐11.69). In contrast to the review at hand, <a href="./references#CD010703-bbs2-0195" title="SateiaMJ , BuysseDJ , KrystalAD , NeubauerDN , HealdJL . Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med2017;13(2):307‐49. ">Sateia 2017</a> included cross‐over trials and provided separate analyses for 2 mg and 3 mg dosing groups. Furthermore, our review excluded medians from pooling of continuous data as suggest by <a href="./references#CD010703-bbs2-0126" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;20(5):1‐10. ">Hozo 2005</a>, which did not allow the inclusion of the largest trial (<a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a>) into meta‐analyses of primary sleep efficacy outcomes. </p> <p>Adverse events identified in the review like unpleasant taste (RD 0.18, 95% CI 0.14 to 0.219), dry mouth (RD 0.04, 95% CI 0.02 to 0.06), somnolence (RD 0.04, 95% CI 0.02 to 0.06) and dizziness (RD 0.03, 95% CI 0.01 to 0.05) have been reported formerly (e.g. <a href="./references#CD010703-bbs2-0113" title="HairPI , McCormackPL , CurranMP . Eszopiclone: a review of its use in the treatment of insomnia. Drugs2008;68(10):1415‐34. ">Hair 2008</a>; <a href="./references#CD010703-bbs2-0167" title="NajibJ . Eszopiclone, a nonbenzodiazepine sedative‐hypnotic agent for the treatment of transient and chronic insomnia. Clinical Therapeutics2006;28(4):491‐516. ">Najib 2006</a>) and are listed in the Lunesta package insert (<a href="./references#CD010703-bbs2-0148" title="Lunesta® (eszopiclone) package insert. Sepracor Inc (Sunovion Pharmaceuticals): Marlborough (MA)2004. ">Lunesta 2004 [pers comm]</a>). In contrast to case‐control studies (<a href="./references#CD010703-bbs2-0067" title="BerrySD , LeeY , CaiS , DoreDD . Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Internal Medicine2013;173(9):754‐61. ">Berry 2013</a>; <a href="./references#CD010703-bbs2-0083" title="DiemSJ , EwingSK , StoneKL , Ancoli‐IsraelS , RedlineS , EnsrudKE , the Osteoporotic Fractures in Men (MrOS) Study Group. Use of non‐benzodiazepine sedative hypnotics and risk of falls in older men. Journal of Gerontology &amp; Geriatric Research2014;3(3):158. ">Diem 2014</a>), subgroup analyses of adverse events in samples of the elderly did not identify an increased risk for serious adverse events like falls, injury, and hip fractures, which might be due to the more controlled conditions in clinical trials compared to everyday life. The exclusion of certain participant subgroups and the monitoring of treatment implementation in clinical research might also explain the absence of central nervous system (CNS) side effects of eszopiclone, such as amnesia or hallucinations, which have previously been reported in case studies for racemic zopiclone (<a href="./references#CD010703-bbs2-0093" title="ElkoCJ , BurgessJL , RobertsonWO . Zolpidem‐associated hallucinations and serotonin reuptake inhibition: a possible interaction.. Journal of Toxicology: Clinical Toxicology1998;36:195–203. ">Elko 1998</a>; <a href="./references#CD010703-bbs2-0210" title="TonerLC , TsambirasBM , CatalanoG . Central nervous system side effects associated with zolpidem treatment. Clinical Neuropharmacology2000;23:54‐8. ">Toner 2000</a>; <a href="./references#CD010703-bbs2-0211" title="TsaiMJ , HuangYB , WuPC . A novel clinical pattern of visual hallucination after zolpidem use. Journal of Toxicology: Clinical Toxicology2003;41:869–72. ">Tsai 2003</a>) and eszopiclone (<a href="./references#CD010703-bbs2-0087" title="DuggalHS . New‐onset transient hallucinations possibly due to eszopiclone: a case study. The Primary Care Companion to the Journal of Clinical Psychiatry2007;9(6):468‐9. ">Duggal 2007</a>), occurring preferably if hypnotic drugs were taken in high doses or if combined with other psychoactive substances. </p> <p>Meta‐analyses of participant‐reported next‐day alertness (MD = 0.46; 95% CI 0.28 to 0.63; 8 RCTs; 2061 participants) did not identify residual effects as currently shown in a randomised, double‐blind cross‐over study (<a href="./references#CD010703-bbs2-0017" title="BoyleJ , GroegerJA , PaskaW , CooperJA , RockettC , JonesS , et al. A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. Journal of Clinical Psychopharmacology2012;32(5):704‐9. ">Boyle 2012</a>). Reasons for divergent results might be found from a lack of the sensitivity of subjective measures in displaying psychomotor and cognitive impairments or the application of sleep restriction protocols in the cross‐over study. Nevertheless, as a restricted sleep protocol might adequately represent 'likely scenarios in insomniacs' (<a href="./references#CD010703-bbs2-0112" title="Gunja , N . In the Zzz zone: the effects of Z‐drugs on human performance and driving. Journal of Medical Toxicology2013;9(2):163‐71. ">Gunja 2013</a>), significant weight might be given to the findings of the cross‐over study (<a href="./references#CD010703-bbs2-0017" title="BoyleJ , GroegerJA , PaskaW , CooperJA , RockettC , JonesS , et al. A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. Journal of Clinical Psychopharmacology2012;32(5):704‐9. ">Boyle 2012</a>). </p> <p>Finally, the review did not identify withdrawal symptoms and distinct rebound effects after eszopiclone was discontinued, supporting the conclusion that, if taken as recommended, eszopiclone has a low potential to cause dependence and withdrawal. Findings from randomised placebo‐controlled studies with racemic zopiclone, which failed to demonstrate polysomnographic withdrawal effects after a four‐week treatment in a recommended dose range (<a href="./references#CD010703-bbs2-0216" title="VoderholzerU , RiemannD , HornyakM , BackhausJ , FeigeB , BergerM , et al. A double‐blind, randomised and placebo‐controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience 2001;251(3):117‐23. ">Vorderholzer 2001</a>) and did not show abuse‐like effects in drug‐naive participants (<a href="./references#CD010703-bbs2-0145" title="LicataSC , PenetarDM , DunlapS , LukasSE . A therapeutic dose of zolpidem has limited abuse‐like effects in drug‐naïve females: a pilot study. European Journal of Pharmacology2008;598(1‐3):64‐7. ">Licata 2008</a>), are consistent with our conclusion. Nevertheless, withdrawal symptoms, craving, and severe rebound insomnia associated with the high dose use of zopiclone in individuals with preexisting chemical abuse or psychiatric disorders, as documented in case reports (<a href="./references#CD010703-bbs2-0078" title="Cimolai , N . Zopiclone. Is it a pharmacologic agent for abuse?. Canadian Family Physician2007;53:2124‐9. ">Cimolai 2007</a>), suggests that safety conclusions might only be valid for the use of eszopiclone in the recommended dose range and without contraindicated substances. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010703-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (search results to Feb 2016)" data-id="CD010703-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (search results to Feb 2016)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010703-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010703-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.1 Sleep onset latency (SOL)." data-id="CD010703-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.1 Sleep onset latency (SOL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.2 Wake time after sleep onset (WASO)." data-id="CD010703-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Eszopiclone versus placebo, outcome: 1.2 Wake time after sleep onset (WASO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 1 Sleep onset latency (SOL)." data-id="CD010703-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 1 Sleep onset latency (SOL).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 2 Wake time after sleep onset (WASO)." data-id="CD010703-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 2 Wake time after sleep onset (WASO).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 3 Withdrawal symptoms." data-id="CD010703-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 3 Withdrawal symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 4 Rebound insomnia." data-id="CD010703-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 4 Rebound insomnia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 5 Total sleep time (TST)." data-id="CD010703-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 5 Total sleep time (TST).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 6 Next‐day alertness." data-id="CD010703-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 6 Next‐day alertness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 7 Adverse events." data-id="CD010703-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 8 Subgroups: insomnia type ‐ SOL." data-id="CD010703-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 8 Subgroups: insomnia type ‐ SOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 9 Subgroups: insomnia type ‐ WASO." data-id="CD010703-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 9 Subgroups: insomnia type ‐ WASO.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 10 Subgroups: insomnia type ‐ TST." data-id="CD010703-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 10 Subgroups: insomnia type ‐ TST.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 11 Subgrups: age groups ‐ SOL." data-id="CD010703-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 11 Subgrups: age groups ‐ SOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 12 Subgroups: age groups ‐ WASO." data-id="CD010703-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 12 Subgroups: age groups ‐ WASO.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 13 Subgroups: age groups ‐ TST." data-id="CD010703-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 13 Subgroups: age groups ‐ TST.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 14 Subgroups: age groups ‐ alertness." data-id="CD010703-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 14 Subgroups: age groups ‐ alertness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 15 Subgroups: older participants ‐ adverse events." data-id="CD010703-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 15 Subgroups: older participants ‐ adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 16 Subgroups: study initiation ‐ SOL." data-id="CD010703-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 16 Subgroups: study initiation ‐ SOL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 17 Subgroups: study initiation ‐ WASO." data-id="CD010703-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 17 Subgroups: study initiation ‐ WASO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 18 Subgroups: study initiation ‐ TST." data-id="CD010703-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 18 Subgroups: study initiation ‐ TST. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 19 Sensitivity: sleep assessment." data-id="CD010703-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 19 Sensitivity: sleep assessment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010703-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/urn:x-wiley:14651858:media:CD010703:CD010703-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_t/tCD010703-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Eszopiclone versus placebo, Outcome 20 Sensitivity: withdrawal assessment." data-id="CD010703-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Eszopiclone versus placebo, Outcome 20 Sensitivity: withdrawal assessment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/media/CDSR/CD010703/image_n/nCD010703-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010703-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eszopiclone for insomnia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Eszopiclone versus placebo for insomnia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with insomnia<br/> <b>Settings:</b> Outpatient<br/> <b>Intervention:</b> Eszopiclone </p> <p><b>Comparator:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Eszopiclone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sleep onset latency</b><br/> Participant reports. Scale from 30 to 540 minutes; </p> <p>fewer minutes equalled better outcome; CFB and double‐blind average values included</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sleep onset latency in the control groups was<br/> <b>20 to 65.7 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean sleep onset latency in the intervention groups was<br/> <b>11.94 minutes lower</b><br/> (16.03 to 7.86 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2890<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wake time after sleep onset</b><br/> Participant reports. Scale from: 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean wake time after sleep onset ranged across control groups from<br/> <b>46 to 78.1 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean wake time after sleep onset in the intervention groups was<br/> <b>17.02 minutes lower</b><br/> (24.89 to 9.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2295<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebound insomnia ‐ sleep onset latency</b><br/> Scale from: 0 to 540 minutes.<br/> Follow‐up: 3 days (14 days); fewer minutes equalled better outcome; CFB were calculated by subtracting the mean average of the first three nights of the placebo run‐out period from initial scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the control group was<br/> <b>‐24.02 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the intervention groups was<br/> <b>17 minutes higher</b><br/> (4.29 lower to 38.29 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rebound insomnia ‐ wake time after sleep onset</b><br/> Scale from: 0 to 540 minutes.<br/> Follow‐up: 3 days (14 days); fewer minutes equalled better outcome; CFB were calculated by subtracting the mean average of the first three nights of the placebo run‐out period from initial scores </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ sleep onset latency in the control group was<br/> <b>‐22.15 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rebound insomnia ‐ wake time after sleep onset in the intervention groups was<br/> <b>6.71 minutes lower</b><br/> (21.25 lower to 7.83 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total sleep time</b><br/> Participant reports. Scale from: 300 to 840; more minutes equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total sleep time ranged across control groups from<br/> <b>324.8 to 382.2 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean total sleep time in the intervention groups was<br/> <b>27.70 minutes higher</b><br/> (20.30 to 35.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2935<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Next‐day alertness</b><br/> Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean next‐day alertness ranged across control groups from<br/> <b>5.7 to 7.3 on a 11‐point Likert Scale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean next‐day alertness in the intervention groups was<br/> <b>0.46 points higher</b><br/> (0.28 to 0.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2061<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Serious adverse events (as defined in the primary study)</b> <br/> Participant reports. Serious adverse events observed during double‐blind treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4289<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b><br/> (‐1 to 19) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> We downgraded evidence for sleep efficacy outcomes and adverse events by one grade due to methodological limitations (omission of specific design features from trial reports; taste properties of eszopiclone potentially revealing the identity of medication).<br/> <sup>2</sup> Even though some inconsistency of results was shown for WASO, heterogeneity was mainly attributable to one trial (<a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a>), whose exclusion resulted into a I<sup>2</sup> reduction from 55% to 6%.<br/> <sup>3</sup> We downgraded evidence for rebound insomnia outcomes by two grades as five RCTs (with a duration &gt; two weeks) applied open‐label extensions, naturalistic follow‐ups or no follow‐up, which we did not consider appropriate to control bias effects </p> <p><sup>4</sup> We downgraded evidence for next‐day alertness assessed through subjective measures by two grades as it was expected to be rather the objective than the subjective measures of next‐day functioning that might determine the risk of harm, including injuries and accidents </p> <p><sup>CFB: Change from baseline</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Eszopiclone for insomnia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010703-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Author</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Female (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Specific sample characteristics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration (weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single‐blind run‐out (days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>— (follow‐up)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS), PSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary); actigraphy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>— (follow‐up)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid Parkinsons disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid anxiety disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comorbid rheumatoid arthritis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elderly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (diary)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (open label)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant reports (IVRS), PSG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>IVRS: interactive voice response system</sup> </p> <p><sup>N: number</sup> </p> <p><sup>PSG: polysomnography</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010703-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates of unpleasant taste</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ESZ (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PBO (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.03</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>ESZ: eszopiclone</sup> </p> <p><sup>PBO: placebo</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates of unpleasant taste</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010703-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of outcome: means and medians</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome statistic</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep efficacy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Rebound insomnia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TST</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sign.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0001" title="Ancoli‐IsraelS , KrystalAD , McCallWV , SchaeferK , WilsonA , ClausR , et al. A 12‐week, randomised, double‐blind, placebo‐controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep2010;33(2):225‐34. ">Ancoli‐Israel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0002" title="FavaM , McCallWV , KrystalA , WesselT , RubensR , CaronJ , et al. Eszopiclone co‐administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biological Psychiatry2006;59(11):1052‐60. ">Fava 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.004</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ns</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0003" title="GoforthHW , Preud'hommeX , KrystalAD . A randomised, double‐blind, placebo‐controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep2014;37(6):1053‐60. ">Goforth 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0004" title="KrystalAD , WalshJK , LaskaE , CaronJ , AmatoDA , WesselTC , et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomised, double‐blind, placebo‐controlled study in adults with chronic insomnia. Sleep2003;26(7):793‐9. ">Krystal 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0005" title="McCallWV , ErmanM , KrystalAD , RosenbergR , ScharfM , ZammitGK , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Current Medical Research and Opinion2006;22(9):1633‐42. ">McCall 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0006" title="McCallWV , BlockerJN , D’AgostinoRBJr , KimballJ , BoggsN , LasaterB , et al. Treatment of insomnia in depressed insomniacs: effects on health‐related quality of life, objective and self reported sleep, and depression. Journal of Clinical Sleep Medicine2010;6:322‐9. ">McCall 2010a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ß, SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.008</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.04</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0007" title="MenzaM , DobkinRD , MarinH , GaraM , BienfaitK , DickeA , et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Movement Disorders2010;25(11):1708‐14. ">Menza 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.071.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0008" title="PollackM , KinrysG , KrystalA , McCallWV , RothT , SchaeferK , et al. Eszopiclone co‐administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Archives of General Psychiatry2008;65(5):551‐62. ">Pollack 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0009" title="RothT , PriceJM , AmatoDA , RubensRP , RoachJM , SchnitzerTJ . The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Primary Care Companion to the Journal of Clinical Psychiatry2009;11(6):292‐301. ">Roth 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.01</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.01</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P = 0.01</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0010" title="ScharfM , ErmanM , RosenbergR , SeidenD , McCallWV , AmatoD , et al. A 2‐week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep2005;28(6):720‐7. ">Scharf 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0011" title="SoaresCN , JoffeH , RubensR , CaronJ , RothT , CohenL . Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomised controlled trial. Obstetrics &amp; Gynecology2006;108(6):1402‐10. ">Soares 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0012" title="SpieringsEL , McAllisterPJ , BilchikTR . Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta) and its effect on total sleep time, headache frequency, and daytime functioning: a randomised, double‐blind, placebo‐controlled, parallel‐group, pilot study. Cranio2015;33(2):115‐21. ">Spierings 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0013" title="WalshJK , KrystalAD , AmatoDA , RubensR , CaronJ , WesselTC , et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep2007;30(8):959‐68. ">Walsh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P &lt; 0.001</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010703-bbs2-0014" title="ZammitGK , McNabbLJ , CaronJ , AmatoDA , RothT . Efficacy and safety of eszopiclone across 6‐weeks of treatment for primary insomnia. Current Medical Research and Opinion2004;20(12):1979‐91. ">Zammit 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medians, means</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ns</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>LPS: latency to persistent sleep</p> <p>Nr: not reported</p> <p>Ns: not statistically significant (no quantitative information provided)</p> <p>P: P value</p> <p>SOL: sleep onset latency</p> <p>TST: total sleep time</p> <p>WASO: wake time after sleep onset</p> <p><b>bold: not included in the meta‐analyses</b> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Overview of outcome: means and medians</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/full#CD010703-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010703-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Eszopiclone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sleep onset latency (SOL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.94 [‐16.03, ‐7.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Wake time after sleep onset (WASO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.02 [‐24.89, ‐9.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.00, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Accidental injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Arthritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Backpain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Dysmenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.03, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Hyperesthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Memory impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Neurosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Paresthesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.02, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19 Photosensivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.04, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21 Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23 Any</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Rebound insomnia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.76 [‐18.55, 15.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Rebound ‐ SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.0 [‐4.29, 38.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Rebound ‐ WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.71 [‐21.25, 7.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Rebound ‐ TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.30 [‐36.42, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total sleep time (TST) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.70 [20.30, 35.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Next‐day alertness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.28, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Accidental injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.06, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Backpain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Coughing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 Decreased libido</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Diarrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.15 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.16 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.17 Edema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.18 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.19 Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.20 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.21 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.02, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.22 Memory impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.00, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.23 Mood changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.24 Muscle pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.25 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.26 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.27 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.28 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.29 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.30 Poor concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.31 Respiratory infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.32 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.33 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.34 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.35 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.36 Unpleasant taste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.14, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroups: insomnia type ‐ SOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.25 [‐16.99, ‐7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Primary insomnia: SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.14 [‐21.13, ‐9.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Comorbid insomnia: SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.10 [‐17.77, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroups: insomnia type ‐ WASO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.55 [‐24.76, ‐8.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Primary insomnia: WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.76 [‐25.60, ‐5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Comorbid insomnia: WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.20 [‐40.76, ‐1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroups: insomnia type ‐ TST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.37 [20.16, 36.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Primary insomnia: TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.04 [19.09, 40.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Secondary insomnia: TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.37 [12.61, 34.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Subgrups: age groups ‐ SOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.48 [‐16.92, ‐8.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Younger age ‐ SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.08 [‐19.15, ‐7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Older age ‐ SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.41 [‐20.37, ‐2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Subgroups: age groups ‐ WASO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.55 [‐24.76, ‐8.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Younger age ‐ WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.20 [‐19.02, ‐5.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Older age ‐ WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.16 [‐40.70, ‐3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Subgroups: age groups ‐ TST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.54 [21.81, 35.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Younger age ‐ TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.66 [21.60, 37.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Older age ‐ TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.01 [11.83, 42.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Subgroups: age groups ‐ alertness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.26, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Younger age: next‐day alertness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.37, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Older age: next‐day alertness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Subgroups: older participants ‐ adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Dropout</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Accidental injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 Arthralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 Backpain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.9 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.10 Edema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.11 Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.12 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.13 Memory impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.00, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.14 Mood changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.15 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.00, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.16 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.17 Pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.18 Poor concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.19 Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.20 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.21 Unpleasant taste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.08, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Subgroups: study initiation ‐ SOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Investigator‐initiated ‐ SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.29 [‐14.24, ‐2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Sponsor‐initiated ‐ SOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.21 [‐20.83, ‐9.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Subgroups: study initiation ‐ WASO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Investigator‐initiated WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.29 [‐56.47, ‐10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Sponsor‐initiated WASO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.31 [‐23.50, ‐7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Subgroups: study initiation ‐ TST <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Investigator‐initiated TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.04 [‐4.19, 46.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Sponsor‐initiated TST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.40 [19.60, 37.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Sensitivity: sleep assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.92 [‐13.32, ‐6.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Sleep onset latency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.50 [‐19.89, ‐11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Wake time after sleep onset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.37 [‐18.61, ‐6.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Total sleep time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.6 [18.14, 39.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Sensitivity: withdrawal assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Eszopiclone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010703.pub2/references#CD010703-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010703.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010703-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010703-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010703-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010703-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010703-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010703-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD010703-note-0002">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010703\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010703\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010703\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010703\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010703\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010703.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010703.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010703.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010703.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010703.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724643725"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010703.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724643729"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010703.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e67d46a171c00',t:'MTc0MDcyNDY0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 